<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Antivirals: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i391.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i391.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i391.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i390.htm" title="Previous: Zuclopenthixol">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i1216.htm" title="Next: Telaprevir">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i391">Antivirals</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Antivirals</b>
          has no specific interaction information.
        </p><p><b>Telaprevir</b> belongs to
      <b>Antivirals</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

























































<tr><td><a href="41001i30.htm">Alfuzosin</a></td><td class="cBV"><b>manufacturer of  telaprevir advises avoid concomitant use with alfuzosin </b></td><td></td></tr><tr><td><a href="41001i118.htm">Amiodarone</a></td><td class="cBV"><b>manufacturer of  telaprevir advises avoid concomitant use with amiodarone (risk of ventricular arrhythmias)</b></td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i470.htm">Amlodipine</a></td><td> telaprevir increases plasma concentration of amlodipine (consider reducing dose of amlodipine)</td><td></td></tr><tr><td><a href="41001i1005.htm">Atazanavir</a></td><td>plasma concentration of  telaprevir possibly reduced by atazanavir , also plasma concentration of atazanavir possibly increased</td><td></td></tr><tr><td><a href="41001i601.htm">Atorvastatin</a></td><td class="cBV"><b>manufacturer of  telaprevir advises avoid concomitant use with atorvastatin </b></td><td></td></tr><tr><td><a href="41001i943.htm">Bosentan</a></td><td>plasma concentration of  telaprevir possibly reduced by bosentan , also plasma concentration of bosentan possibly increased</td><td></td></tr><tr><td><a href="41001i496.htm">Budesonide</a></td><td> telaprevir possibly increases plasma concentration of <i>inhaled</i> and <i>intranasal</i> budesonide </td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td class="cBV"><b>manufacturer of  telaprevir advises avoid concomitant use with carbamazepine </b></td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b>plasma concentration of both drugs increased when  telaprevir given with ciclosporin (reduce dose of ciclosporin)</b></td><td></td></tr><tr><td><a href="41001i168.htm">Clarithromycin</a></td><td class="cBV"><b>plasma concentration of both drugs possibly increased when  telaprevir given with clarithromycin (increased risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i483.htm">Colchicine</a></td><td class="cBV"><b> telaprevir possibly increases risk of colchicine toxicity—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)</b></td><td></td></tr><tr><td><a href="41001i1120.htm">Dabigatran Etexilate</a></td><td> telaprevir possibly increases plasma concentration of dabigatran etexilate </td><td></td></tr><tr><td><a href="41001i1091.htm">Darunavir</a></td><td class="cBV"><b>manufacturer of  telaprevir advises avoid concomitant use with darunavir </b></td><td></td></tr><tr><td><a href="41001i490.htm">Dexamethasone</a></td><td>plasma concentration of  telaprevir possibly reduced by dexamethasone </td><td></td></tr><tr><td><a href="41001i480.htm">Digoxin</a></td><td> telaprevir increases plasma concentration of digoxin </td><td></td></tr><tr><td><a href="41001i468.htm">Diltiazem</a></td><td>manufacturer of  telaprevir advises caution with diltiazem </td><td></td></tr><tr><td><a href="41001i119.htm">Disopyramide</a></td><td class="cBV"><b>manufacturer of  telaprevir advises avoid concomitant use with disopyramide (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i553.htm">Domperidone</a></td><td class="cBV"><b> telaprevir possibly increases plasma concentration of  domperidone—manufacturer of telaprevir advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td class="cBV"><b>plasma concentration of  telaprevir reduced by efavirenz—increase dose of telaprevir</b></td><td></td></tr><tr><td><a href="41001i981.htm">Ergot Alkaloids</a></td><td class="cBV"><b>manufacturer of  telaprevir advises avoid concomitant use with ergot alkaloids </b></td><td></td></tr><tr><td><a href="41001i169.htm">Erythromycin</a></td><td class="cBV"><b>plasma concentration of both drugs possibly increased when  telaprevir given with erythromycin (increased risk of ventricular arrhythmias)</b></td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i638.htm">Ethinylestradiol</a></td><td class="cBV"><b> telaprevir possibly reduces plasma concentration of ethinylestradiol—manufacturer of telaprevir advises additional contraceptive precautions</b></td><td></td></tr><tr><td><a href="41001i471.htm">Felodipine</a></td><td>manufacturer of  telaprevir advises caution with felodipine </td><td></td></tr><tr><td><a href="41001i120.htm">Flecainide</a></td><td class="cBV"><b>manufacturer of  telaprevir advises caution with flecainide (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i497.htm">Fluticasone</a></td><td> telaprevir possibly increases plasma concentration of <i>inhaled</i> and <i>intranasal</i> fluticasone </td><td></td></tr><tr><td><a href="41001i1019.htm">Fosamprenavir</a></td><td class="cBV"><b>manufacturer of  telaprevir advises avoid concomitant use with fosamprenavir </b></td><td>Fosamprenavir is a prodrug of amprenavir</td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td> telaprevir possibly increases plasma concentration of itraconazole </td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td class="cBV"><b>plasma concentration of both drugs possibly increased when  telaprevir given with ketoconazole (increased risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i55.htm">Lidocaine</a></td><td>manufacturer of  telaprevir advises caution with <i>intravenous</i> lidocaine </td><td>Interactions less likely when lidocaine used topically</td></tr><tr><td><a href="41001i922.htm">Lopinavir</a></td><td class="cBV"><b>manufacturer of  telaprevir advises avoid concomitant use with lopinavir </b></td><td>In combination with ritonavir as <i>Kaletra</i>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</td></tr><tr><td><a href="41001i97.htm">Methadone</a></td><td class="cBV"><b>manufacturer of  telaprevir advises caution with methadone (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i421.htm">Midazolam</a></td><td class="cBV"><b> telaprevir possibly increases plasma concentration of midazolam (risk of prolonged sedation—avoid concomitant use of <i>oral</i> midazolam)</b></td><td></td></tr><tr><td><a href="41001i474.htm">Nicardipine</a></td><td>manufacturer of  telaprevir advises caution with nicardipine </td><td></td></tr><tr><td><a href="41001i475.htm">Nifedipine</a></td><td>manufacturer of  telaprevir advises caution with nifedipine </td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td class="cBV"><b>manufacturer of  telaprevir advises avoid concomitant use with phenobarbital </b></td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b>manufacturer of  telaprevir advises avoid concomitant use with phenytoin </b></td><td></td></tr><tr><td><a href="41001i369.htm">Pimozide</a></td><td class="cBV"><b>manufacturer of  telaprevir advises avoid concomitant use with pimozide </b></td><td></td></tr><tr><td><a href="41001i1060.htm">Posaconazole</a></td><td class="cBV"><b> telaprevir possibly increases plasma concentration of posaconazole (increased risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i125.htm">Propafenone</a></td><td class="cBV"><b>manufacturer of  telaprevir advises caution with propafenone (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i200.htm">Rifabutin</a></td><td class="cBV"><b>manufacturer of  telaprevir advises avoid concomitant use with rifabutin </b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b> telaprevir significantly reduces plasma concentration of rifampicin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td>plasma concentration of  telaprevir possibly reduced by ritonavir </td><td></td></tr><tr><td><a href="41001i727.htm">Salmeterol</a></td><td class="cBV"><b>manufacturer of  telaprevir advises avoid concomitant use with salmeterol (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i858.htm">Sildenafil</a></td><td class="cBV"><b>manufacturer of  telaprevir advises avoid concomitant use with sildenafil </b></td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td class="cBV"><b>manufacturer of  telaprevir advises avoid concomitant use with simvastatin </b></td><td></td></tr><tr><td><a href="41001i921.htm">Sirolimus</a></td><td class="cBV"><b>plasma concentration of both drugs increased when  telaprevir given with sirolimus (reduce dose of sirolimus)</b></td><td></td></tr><tr><td><a href="41001i455.htm">Sotalol</a></td><td class="cBV"><b>manufacturer of  telaprevir advises avoid concomitant use with sotalol (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>manufacturer of  telaprevir advises avoid concomitant use with St John's wort </b></td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td class="cBV"><b>plasma concentration of both drugs increased when  telaprevir given with tacrolimus (reduce dose of tacrolimus)</b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i945.htm">Tadalafil</a></td><td class="cBV"><b>manufacturer of  telaprevir advises avoid concomitant use with high doses of tadalafil—consult product literature</b></td><td></td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td class="cBV"><b>plasma concentration of both drugs possibly increased when  telaprevir given with telithromycin (increased risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i954.htm">Tenofovir</a></td><td> telaprevir increases plasma concentration of tenofovir </td><td></td></tr><tr><td><a href="41001i255.htm">Trazodone</a></td><td> telaprevir possibly increases plasma concentration of trazodone </td><td></td></tr><tr><td><a href="41001i967.htm">Vardenafil</a></td><td class="cBV"><b>manufacturer of  telaprevir advises avoid concomitant use with vardenafil </b></td><td></td></tr><tr><td><a href="41001i467.htm">Verapamil</a></td><td>manufacturer of  telaprevir advises caution with verapamil </td><td></td></tr><tr><td><a href="41001i948.htm">Voriconazole</a></td><td class="cBV"><b> telaprevir possibly affects plasma concentration of voriconazole (possible increased risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i222.htm">Warfarin</a></td><td class="cBV"><b> telaprevir possibly affects plasma concentration of warfarin </b></td><td></td></tr></tbody></table><p><b>Boceprevir</b> belongs to
      <b>Antivirals</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>




















<tr><td><a href="41001i937.htm">Artemether with Lumefantrine</a></td><td class="cBV"><b>manufacturer of  boceprevir advises avoid concomitant use with artemether/lumefantrine </b></td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td class="cBV"><b>manufacturer of  boceprevir advises avoid concomitant use with carbamazepine (plasma concentration of boceprevir possibly reduced)</b></td><td></td></tr><tr><td><a href="41001i1077.htm">Dasatinib</a></td><td class="cBV"><b>manufacturer of  boceprevir advises avoid concomitant use with dasatinib </b></td><td></td></tr><tr><td><a href="41001i962.htm">Drospirenone</a></td><td> boceprevir increases plasma concentration of drospirenone (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i981.htm">Ergot Alkaloids</a></td><td class="cBV"><b>manufacturer of  boceprevir advises avoid concomitant use with ergot alkaloids </b></td><td></td></tr><tr><td><a href="41001i1048.htm">Erlotinib</a></td><td class="cBV"><b>manufacturer of  boceprevir advises avoid concomitant use with erlotinib </b></td><td></td></tr><tr><td><a href="41001i1170.htm">Gefitinib</a></td><td class="cBV"><b>manufacturer of  boceprevir advises avoid concomitant use with gefitinib </b></td><td></td></tr><tr><td><a href="41001i933.htm">Imatinib</a></td><td class="cBV"><b>manufacturer of  boceprevir advises avoid concomitant use with imatinib </b></td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td class="cBV"><b>plasma concentration of  boceprevir increased by ketoconazole </b></td><td></td></tr><tr><td><a href="41001i1128.htm">Lapatinib</a></td><td class="cBV"><b>manufacturer of  boceprevir advises avoid concomitant use with lapatinib </b></td><td></td></tr><tr><td><a href="41001i421.htm">Midazolam</a></td><td class="cBV"><b> boceprevir increases plasma concentration of <i>oral</i> midazolam—manufacturer of boceprevir advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1118.htm">Nilotinib</a></td><td class="cBV"><b>manufacturer of  boceprevir advises avoid concomitant use with nilotinib </b></td><td></td></tr><tr><td><a href="41001i636.htm">Oestrogens</a></td><td class="cBV"><b> boceprevir possibly causes contraceptive failure of hormonal contraceptives containing oestrogens (alternative contraception recommended)</b></td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="4552.htm#_120026">section 7.3.1</a></td></tr><tr><td><a href="41001i1186.htm">Pazopanib</a></td><td class="cBV"><b>manufacturer of  boceprevir advises avoid concomitant use with pazopanib </b></td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td class="cBV"><b>manufacturer of  boceprevir advises avoid concomitant use with phenobarbital (plasma concentration of boceprevir possibly reduced)</b></td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b>manufacturer of  boceprevir advises avoid concomitant use with phenytoin (plasma concentration of boceprevir possibly reduced)</b></td><td></td></tr><tr><td><a href="41001i369.htm">Pimozide</a></td><td class="cBV"><b>manufacturer of  boceprevir advises avoid concomitant use with pimozide </b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>manufacturer of  boceprevir advises avoid concomitant use with rifampicin (plasma concentration of boceprevir possibly reduced)</b></td><td></td></tr><tr><td><a href="41001i1074.htm">Sorafenib</a></td><td class="cBV"><b>manufacturer of  boceprevir advises avoid concomitant use with sorafenib </b></td><td></td></tr><tr><td><a href="41001i1075.htm">Sunitinib</a></td><td class="cBV"><b>manufacturer of  boceprevir advises avoid concomitant use with sunitinib </b></td><td></td></tr></tbody></table><p><b>Etravirine</b> belongs to
      <b>Antivirals</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


















<tr><td><a href="41001i601.htm">Atorvastatin</a></td><td> etravirine possibly reduces plasma concentration of atorvastatin </td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td>manufacturer of  etravirine advises avoid concomitant use with carbamazepine </td><td></td></tr><tr><td><a href="41001i168.htm">Clarithromycin</a></td><td class="cBV"><b>plasma concentration of  etravirine increased by clarithromycin , also plasma concentration of clarithromycin reduced</b></td><td></td></tr><tr><td><a href="41001i865.htm">Clopidogrel</a></td><td class="cBV"><b> etravirine possibly reduces antiplatelet effect of clopidogrel </b></td><td></td></tr><tr><td><a href="41001i480.htm">Digoxin</a></td><td> etravirine increases plasma concentration of digoxin </td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td class="cBV"><b>plasma concentration of  etravirine possibly reduced by efavirenz—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1019.htm">Fosamprenavir</a></td><td class="cBV"><b> etravirine increases plasma concentration of fosamprenavir (consider reducing dose of fosamprenavir)</b></td><td>Fosamprenavir is a prodrug of amprenavir</td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td class="cBV"><b> etravirine possibly reduces plasma concentration of indinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1107.htm">Maraviroc</a></td><td> etravirine possibly reduces plasma concentration of maraviroc </td><td></td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td> etravirine possibly increases plasma concentration of nelfinavir—avoid concomitant use</td><td></td></tr><tr><td><a href="41001i843.htm">Nevirapine</a></td><td class="cBV"><b>plasma concentration of  etravirine possibly reduced by nevirapine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td>manufacturer of  etravirine advises avoid concomitant use with phenobarbital </td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td>manufacturer of  etravirine advises avoid concomitant use with phenytoin </td><td></td></tr><tr><td><a href="41001i200.htm">Rifabutin</a></td><td class="cBV"><b>plasma concentration of both drugs reduced when  etravirine given with rifabutin </b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>manufacturer of  etravirine advises avoid concomitant use with rifampicin </td><td></td></tr><tr><td><a href="41001i858.htm">Sildenafil</a></td><td> etravirine reduces plasma concentration of sildenafil </td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td>manufacturer of  etravirine advises avoid concomitant use with St John's wort </td><td></td></tr><tr><td><a href="41001i1055.htm">Tipranavir</a></td><td class="cBV"><b>plasma concentration of  etravirine reduced by tipranavir , also plasma concentration of tipranavir increased (avoid concomitant use)</b></td><td></td></tr></tbody></table><p><b>Fosamprenavir</b> belongs to
      <b>Antivirals</b>
          and has the following interaction information:
        </p><div>Fosamprenavir is a prodrug of amprenavir</div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>








































<tr><td><a href="41001i118.htm">Amiodarone</a></td><td class="cBV"><b> fosamprenavir possibly increases plasma concentration of amiodarone (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i1217.htm">Apixaban</a></td><td>avoidance of  fosamprenavir advised by manufacturer of apixaban </td><td></td></tr><tr><td><a href="41001i1011.htm">Aripiprazole</a></td><td class="cBV"><b> fosamprenavir possibly inhibits metabolism of aripiprazole (reduce dose of aripiprazole)</b></td><td></td></tr><tr><td><a href="41001i937.htm">Artemether with Lumefantrine</a></td><td>caution with  fosamprenavir advised by manufacturer of artemether/lumefantrine </td><td></td></tr><tr><td><a href="41001i601.htm">Atorvastatin</a></td><td>possible increased risk of myopathy when  fosamprenavir given with atorvastatin </td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td>plasma concentration of  fosamprenavir possibly reduced by carbamazepine </td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b> fosamprenavir increases plasma concentration of ciclosporin </b></td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td> fosamprenavir may enhance or reduce anticoagulant effect of coumarins </td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i1076.htm">Darifenacin</a></td><td>avoidance of  fosamprenavir advised by manufacturer of darifenacin </td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td>plasma concentration of  fosamprenavir reduced by efavirenz </td><td></td></tr><tr><td><a href="41001i563.htm">Ergotamine and Methysergide</a></td><td class="cBV"><b>increased risk of ergotism when  fosamprenavir given with ergotamine and methysergide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1135.htm">Etravirine</a></td><td class="cBV"><b>plasma concentration of  fosamprenavir increased by etravirine (consider reducing dose of fosamprenavir)</b></td><td></td></tr><tr><td><a href="41001i120.htm">Flecainide</a></td><td class="cBV"><b> fosamprenavir possibly increases plasma concentration of flecainide (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td>plasma concentration of both drugs may increase when  fosamprenavir given with itraconazole </td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td> fosamprenavir increases plasma concentration of ketoconazole (also plasma concentration of fosamprenavir possibly increased)</td><td></td></tr><tr><td><a href="41001i55.htm">Lidocaine</a></td><td class="cBV"><b> fosamprenavir possibly increases plasma concentration of lidocaine—avoid concomitant use</b></td><td>Interactions less likely when lidocaine used topically</td></tr><tr><td><a href="41001i922.htm">Lopinavir</a></td><td>plasma concentration of  fosamprenavir reduced by lopinavir , effect on lopinavir plasma concentration not predictable—avoid concomitant use</td><td>In combination with ritonavir as <i>Kaletra</i>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</td></tr><tr><td><a href="41001i97.htm">Methadone</a></td><td> fosamprenavir reduces plasma concentration of methadone </td><td></td></tr><tr><td><a href="41001i421.htm">Midazolam</a></td><td class="cBV"><b> fosamprenavir possibly increases plasma concentration of midazolam (risk of prolonged sedation—avoid concomitant use of <i>oral</i> midazolam)</b></td><td></td></tr><tr><td><a href="41001i843.htm">Nevirapine</a></td><td>plasma concentration of  fosamprenavir possibly reduced by nevirapine </td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td>plasma concentration of  fosamprenavir possibly reduced by phenobarbital </td><td></td></tr><tr><td><a href="41001i369.htm">Pimozide</a></td><td class="cBV"><b> fosamprenavir increases plasma concentration of pimozide (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i125.htm">Propafenone</a></td><td class="cBV"><b> fosamprenavir possibly increases plasma concentration of propafenone (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i824.htm">Quetiapine</a></td><td class="cBV"><b> fosamprenavir possibly increases plasma concentration of quetiapine—manufacturer of quetiapine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i341.htm">Quinine</a></td><td class="cBV"><b> fosamprenavir possibly increases plasma concentration of quinine (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i1147.htm">Ranolazine</a></td><td class="cBV"><b> fosamprenavir possibly increases plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i200.htm">Rifabutin</a></td><td class="cBV"><b> fosamprenavir increases plasma concentration of rifabutin (reduce dose of rifabutin)</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>plasma concentration of  fosamprenavir significantly reduced by rifampicin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1136.htm">Rivaroxaban</a></td><td>avoidance of  fosamprenavir advised by manufacturer of rivaroxaban </td><td></td></tr><tr><td><a href="41001i974.htm">Rosuvastatin</a></td><td class="cBV"><b>possible increased risk of myopathy when  fosamprenavir given with rosuvastatin—manufacturer of rosuvastatin advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i858.htm">Sildenafil</a></td><td> fosamprenavir possibly increases plasma concentration of sildenafil </td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td class="cBV"><b>possible increased risk of myopathy when  fosamprenavir given with simvastatin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>plasma concentration of  fosamprenavir reduced by St John's wort—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td class="cBV"><b> fosamprenavir increases plasma concentration of tacrolimus </b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i945.htm">Tadalafil</a></td><td> fosamprenavir possibly increases plasma concentration of tadalafil </td><td></td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td class="cBV"><b>avoidance of  fosamprenavir advised by manufacturer of telaprevir </b></td><td></td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td class="cBV"><b>avoidance of concomitant  fosamprenavir in severe renal and hepatic impairment advised by manufacturer of telithromycin </b></td><td></td></tr><tr><td><a href="41001i1055.htm">Tipranavir</a></td><td class="cBV"><b>plasma concentration of  fosamprenavir reduced by tipranavir </b></td><td></td></tr><tr><td><a href="41001i850.htm">Tolterodine</a></td><td>avoidance of  fosamprenavir advised by manufacturer of tolterodine </td><td></td></tr><tr><td><a href="41001i967.htm">Vardenafil</a></td><td> fosamprenavir possibly increases plasma concentration of vardenafil </td><td></td></tr></tbody></table><p><b>Telbivudine</b> belongs to
      <b>Antivirals</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i586.htm">Interferon Alfa</a></td><td class="cBV"><b>increased risk of peripheral neuropathy when  telbivudine given with interferon alfa </b></td><td></td></tr></tbody></table><p><b>Raltegravir</b> belongs to
      <b>Antivirals</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>




<tr><td><a href="41001i743.htm">Histamine H<sub>2</sub>-antagonists</a></td><td>plasma concentration of  raltegravir possibly increased by histamine H<sub>2</sub>-antagonists—manufacturer of raltegravir advises avoid concomitant use</td><td></td></tr><tr><td><a href="41001i752.htm">Omeprazole</a></td><td class="cBV"><b>plasma concentration of  raltegravir increased by omeprazole—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i751.htm">Proton Pump Inhibitors</a></td><td>plasma concentration of  raltegravir possibly increased by proton pump inhibitors—manufacturer of raltegravir advises avoid concomitant use</td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>plasma concentration of  raltegravir reduced by rifampicin—consider increasing dose of raltegravir</b></td><td></td></tr></tbody></table><p><b>Maraviroc</b> belongs to
      <b>Antivirals</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>














<tr><td><a href="41001i1005.htm">Atazanavir</a></td><td class="cBV"><b>plasma concentration of  maraviroc increased by atazanavir (consider reducing dose of maraviroc)</b></td><td></td></tr><tr><td><a href="41001i168.htm">Clarithromycin</a></td><td class="cBV"><b>plasma concentration of  maraviroc possibly increased by clarithromycin (consider reducing dose of maraviroc)</b></td><td></td></tr><tr><td><a href="41001i1091.htm">Darunavir</a></td><td class="cBV"><b>plasma concentration of  maraviroc increased by darunavir (consider reducing dose of maraviroc)</b></td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td class="cBV"><b>plasma concentration of  maraviroc possibly reduced by efavirenz—consider increasing dose of maraviroc</b></td><td></td></tr><tr><td><a href="41001i1135.htm">Etravirine</a></td><td>plasma concentration of  maraviroc possibly reduced by etravirine </td><td></td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td class="cBV"><b>plasma concentration of  maraviroc increased by indinavir (consider reducing dose of maraviroc)</b></td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td class="cBV"><b>plasma concentration of  maraviroc increased by ketoconazole (consider reducing dose of maraviroc)</b></td><td></td></tr><tr><td><a href="41001i922.htm">Lopinavir</a></td><td class="cBV"><b>plasma concentration of  maraviroc increased by lopinavir (consider reducing dose of maraviroc)</b></td><td>In combination with ritonavir as <i>Kaletra</i>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td class="cBV"><b>plasma concentration of  maraviroc possibly increased by nelfinavir (consider reducing dose of maraviroc)</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>plasma concentration of  maraviroc reduced by rifampicin—consider increasing dose of maraviroc</b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td>plasma concentration of  maraviroc increased by ritonavir </td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>plasma concentration of  maraviroc increased by saquinavir (consider reducing dose of maraviroc)</b></td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>plasma concentration of  maraviroc possibly reduced by St John's wort—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td class="cBV"><b>plasma concentration of  maraviroc possibly increased by telithromycin (consider reducing dose of maraviroc)</b></td><td></td></tr></tbody></table><p><b>Darunavir</b> belongs to
      <b>Antivirals</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


























<tr><td><a href="41001i1217.htm">Apixaban</a></td><td>avoidance of  darunavir advised by manufacturer of apixaban </td><td></td></tr><tr><td><a href="41001i937.htm">Artemether with Lumefantrine</a></td><td>caution with  darunavir advised by manufacturer of artemether/lumefantrine </td><td></td></tr><tr><td><a href="41001i601.htm">Atorvastatin</a></td><td>possible increased risk of myopathy when  darunavir given with atorvastatin </td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td>plasma concentration of  darunavir possibly reduced by carbamazepine </td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td>plasma concentration of  darunavir reduced by efavirenz </td><td></td></tr><tr><td><a href="41001i1169.htm">Everolimus</a></td><td class="cBV"><b> darunavir possibly increases plasma concentration of everolimus—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td>plasma concentration of both drugs increased when  darunavir given with indinavir </td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td>plasma concentration of both drugs increased when  darunavir given with ketoconazole </td><td></td></tr><tr><td><a href="41001i55.htm">Lidocaine</a></td><td> darunavir possibly increases plasma concentration of lidocaine—avoid concomitant use</td><td>Interactions less likely when lidocaine used topically</td></tr><tr><td><a href="41001i922.htm">Lopinavir</a></td><td class="cBV"><b>plasma concentration of  darunavir reduced by lopinavir , also plasma concentration of lopinavir increased (avoid concomitant use)</b></td><td>In combination with ritonavir as <i>Kaletra</i>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</td></tr><tr><td><a href="41001i1107.htm">Maraviroc</a></td><td class="cBV"><b> darunavir increases plasma concentration of maraviroc (consider reducing dose of maraviroc)</b></td><td></td></tr><tr><td><a href="41001i236.htm">Paroxetine</a></td><td> darunavir possibly reduces plasma concentration of paroxetine </td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td>plasma concentration of  darunavir possibly reduced by phenobarbital </td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td>plasma concentration of  darunavir possibly reduced by phenytoin </td><td></td></tr><tr><td><a href="41001i604.htm">Pravastatin</a></td><td> darunavir possibly increases plasma concentration of pravastatin </td><td></td></tr><tr><td><a href="41001i824.htm">Quetiapine</a></td><td class="cBV"><b> darunavir possibly increases plasma concentration of quetiapine—manufacturer of quetiapine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i341.htm">Quinine</a></td><td class="cBV"><b> darunavir possibly increases plasma concentration of quinine (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i1147.htm">Ranolazine</a></td><td class="cBV"><b> darunavir possibly increases plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i200.htm">Rifabutin</a></td><td class="cBV"><b> darunavir increases plasma concentration of rifabutin (reduce dose of rifabutin)</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>plasma concentration of  darunavir significantly reduced by rifampicin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1136.htm">Rivaroxaban</a></td><td>avoidance of  darunavir advised by manufacturer of rivaroxaban </td><td></td></tr><tr><td><a href="41001i974.htm">Rosuvastatin</a></td><td class="cBV"><b>possible increased risk of myopathy when  darunavir given with rosuvastatin—manufacturer of rosuvastatin advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td>plasma concentration of  darunavir reduced by saquinavir </td><td></td></tr><tr><td><a href="41001i237.htm">Sertraline</a></td><td> darunavir possibly reduces plasma concentration of sertraline </td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>plasma concentration of  darunavir reduced by St John's wort—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td class="cBV"><b>avoidance of  darunavir advised by manufacturer of telaprevir </b></td><td></td></tr></tbody></table><p><b>Adefovir</b> belongs to
      <b>Antivirals</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i954.htm">Tenofovir</a></td><td>avoidance of  adefovir advised by manufacturer of tenofovir </td><td></td></tr></tbody></table><p><b>Tipranavir</b> belongs to
      <b>Antivirals</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


































<tr><td><a href="41001i907.htm">Abacavir</a></td><td class="cBV"><b> tipranavir reduces plasma concentration of abacavir </b></td><td></td></tr><tr><td><a href="41001i110.htm">Antacids</a></td><td>absorption of  tipranavir reduced by antacids </td><td>Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</td></tr><tr><td><a href="41001i1217.htm">Apixaban</a></td><td>avoidance of  tipranavir advised by manufacturer of apixaban </td><td></td></tr><tr><td><a href="41001i937.htm">Artemether with Lumefantrine</a></td><td>caution with  tipranavir advised by manufacturer of artemether/lumefantrine </td><td></td></tr><tr><td><a href="41001i1005.htm">Atazanavir</a></td><td>plasma concentration of  tipranavir increased by atazanavir (also plasma concentration of atazanavir reduced)</td><td></td></tr><tr><td><a href="41001i601.htm">Atorvastatin</a></td><td class="cBV"><b> tipranavir increases plasma concentration of atorvastatin (increased risk of myopathy—reduce dose of atorvastatin)</b></td><td></td></tr><tr><td><a href="41001i943.htm">Bosentan</a></td><td>manufacturer of  tipranavir advises avoid concomitant use with bosentan </td><td></td></tr><tr><td><a href="41001i87.htm">Buprenorphine</a></td><td>plasma concentration of  tipranavir possibly reduced by buprenorphine </td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td>plasma concentration of  tipranavir possibly reduced by carbamazepine </td><td></td></tr><tr><td><a href="41001i168.htm">Clarithromycin</a></td><td class="cBV"><b> tipranavir increases plasma concentration of clarithromycin (reduce dose of clarithromycin in renal impairment), also plasma concentration of tipranavir increased by clarithromycin</b></td><td></td></tr><tr><td><a href="41001i1076.htm">Darifenacin</a></td><td>avoidance of  tipranavir advised by manufacturer of darifenacin </td><td></td></tr><tr><td><a href="41001i397.htm">Didanosine</a></td><td class="cBV"><b> tipranavir reduces plasma concentration of didanosine </b></td><td>Antacids in tablet formulation may affect absorption of other drugs</td></tr><tr><td><a href="41001i914.htm">Esomeprazole</a></td><td class="cBV"><b> tipranavir reduces plasma concentration of esomeprazole </b></td><td></td></tr><tr><td><a href="41001i1135.htm">Etravirine</a></td><td class="cBV"><b> tipranavir reduces plasma concentration of etravirine , also plasma concentration of tipranavir increased (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i301.htm">Fluconazole</a></td><td>plasma concentration of  tipranavir increased by fluconazole </td><td>In general, fluconazole interactions relate to multiple-dose treatment</td></tr><tr><td><a href="41001i1019.htm">Fosamprenavir</a></td><td class="cBV"><b> tipranavir reduces plasma concentration of fosamprenavir </b></td><td>Fosamprenavir is a prodrug of amprenavir</td></tr><tr><td><a href="41001i922.htm">Lopinavir</a></td><td class="cBV"><b> tipranavir reduces plasma concentration of lopinavir </b></td><td>In combination with ritonavir as <i>Kaletra</i>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</td></tr><tr><td><a href="41001i451.htm">Metoprolol</a></td><td class="cBV"><b>manufacturer of  tipranavir advises avoid concomitant use with metoprolol for heart failure</b></td><td></td></tr><tr><td><a href="41001i752.htm">Omeprazole</a></td><td class="cBV"><b> tipranavir reduces plasma concentration of omeprazole </b></td><td></td></tr><tr><td><a href="41001i824.htm">Quetiapine</a></td><td class="cBV"><b> tipranavir possibly increases plasma concentration of quetiapine—manufacturer of quetiapine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i341.htm">Quinine</a></td><td class="cBV"><b> tipranavir possibly increases plasma concentration of quinine (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i1147.htm">Ranolazine</a></td><td class="cBV"><b> tipranavir possibly increases plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i200.htm">Rifabutin</a></td><td class="cBV"><b> tipranavir increases plasma concentration of rifabutin (reduce dose of rifabutin)</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>plasma concentration of  tipranavir possibly reduced by rifampicin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1136.htm">Rivaroxaban</a></td><td>avoidance of  tipranavir advised by manufacturer of rivaroxaban </td><td></td></tr><tr><td><a href="41001i974.htm">Rosuvastatin</a></td><td class="cBV"><b> tipranavir possibly increases plasma concentration of rosuvastatin—manufacturer of rosuvastatin advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i727.htm">Salmeterol</a></td><td>manufacturer of  tipranavir advises avoid concomitant use with salmeterol </td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b> tipranavir reduces plasma concentration of saquinavir </b></td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td class="cBV"><b> tipranavir possibly increases plasma concentration of simvastatin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>plasma concentration of  tipranavir possibly reduced by St John's wort—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td class="cBV"><b>avoidance of concomitant  tipranavir in severe renal and hepatic impairment advised by manufacturer of telithromycin </b></td><td></td></tr><tr><td><a href="41001i967.htm">Vardenafil</a></td><td>manufacturer of  tipranavir advises caution with vardenafil </td><td></td></tr><tr><td><a href="41001i1134.htm">Vitamin E</a></td><td>increased risk of bleeding when  tipranavir given with high doses of vitamin E </td><td></td></tr><tr><td><a href="41001i403.htm">Zidovudine</a></td><td class="cBV"><b> tipranavir reduces plasma concentration of zidovudine </b></td><td>Increased risk of toxicity with nephrotoxic and myelosuppressive drugs—for further details consult product literature</td></tr></tbody></table><p><b>Atazanavir</b> belongs to
      <b>Antivirals</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

















































<tr><td><a href="41001i118.htm">Amiodarone</a></td><td class="cBV"><b> atazanavir possibly increases plasma concentration of amiodarone </b></td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i110.htm">Antacids</a></td><td>plasma concentration of  atazanavir possibly reduced by antacids </td><td>Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</td></tr><tr><td><a href="41001i1217.htm">Apixaban</a></td><td>avoidance of  atazanavir advised by manufacturer of apixaban </td><td></td></tr><tr><td><a href="41001i1011.htm">Aripiprazole</a></td><td class="cBV"><b> atazanavir possibly inhibits metabolism of aripiprazole (reduce dose of aripiprazole)</b></td><td></td></tr><tr><td><a href="41001i937.htm">Artemether with Lumefantrine</a></td><td>caution with  atazanavir advised by manufacturer of artemether/lumefantrine </td><td></td></tr><tr><td><a href="41001i601.htm">Atorvastatin</a></td><td>possible increased risk of myopathy when  atazanavir given with atorvastatin </td><td></td></tr><tr><td><a href="41001i1204.htm">Cabazitaxel</a></td><td class="cBV"><b>avoidance of  atazanavir advised by manufacturer of cabazitaxel </b></td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b> atazanavir possibly increases plasma concentration of ciclosporin </b></td><td></td></tr><tr><td><a href="41001i168.htm">Clarithromycin</a></td><td>plasma concentration of both drugs increased when  atazanavir given with clarithromycin </td><td></td></tr><tr><td><a href="41001i483.htm">Colchicine</a></td><td class="cBV"><b> atazanavir possibly increases risk of colchicine toxicity—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)</b></td><td></td></tr><tr><td><a href="41001i1076.htm">Darifenacin</a></td><td>avoidance of  atazanavir advised by manufacturer of darifenacin </td><td></td></tr><tr><td><a href="41001i468.htm">Diltiazem</a></td><td class="cBV"><b> atazanavir increases plasma concentration of diltiazem (reduce dose of diltiazem)</b></td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td class="cBV"><b>manufacturer of  atazanavir advises avoid concomitant use with efavirenz (plasma concentration of atazanavir reduced)</b></td><td></td></tr><tr><td><a href="41001i981.htm">Ergot Alkaloids</a></td><td class="cBV"><b> atazanavir possibly increases plasma concentration of ergot alkaloids—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i638.htm">Ethinylestradiol</a></td><td> atazanavir increases plasma concentration of ethinylestradiol </td><td></td></tr><tr><td><a href="41001i1169.htm">Everolimus</a></td><td class="cBV"><b> atazanavir possibly increases plasma concentration of everolimus—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1119.htm">Fesoterodine</a></td><td>manufacturer of fesoterodine advises dose reduction when  atazanavir given with fesoterodine—consult fesoterodine product literature</td><td></td></tr><tr><td><a href="41001i743.htm">Histamine H<sub>2</sub>-antagonists</a></td><td class="cBV"><b>plasma concentration of  atazanavir reduced by histamine H<sub>2</sub>-antagonists </b></td><td></td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td class="cBV"><b>avoid concomitant use of  atazanavir with indinavir </b></td><td></td></tr><tr><td><a href="41001i1006.htm">Irinotecan</a></td><td class="cBV"><b> atazanavir possibly inhibits metabolism of irinotecan (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i55.htm">Lidocaine</a></td><td class="cBV"><b> atazanavir possibly increases plasma concentration of lidocaine </b></td><td>Interactions less likely when lidocaine used topically</td></tr><tr><td><a href="41001i1107.htm">Maraviroc</a></td><td class="cBV"><b> atazanavir increases plasma concentration of maraviroc (consider reducing dose of maraviroc)</b></td><td></td></tr><tr><td><a href="41001i421.htm">Midazolam</a></td><td class="cBV"><b> atazanavir possibly increases plasma concentration of midazolam—avoid concomitant use of <i>oral</i> midazolam</b></td><td></td></tr><tr><td><a href="41001i843.htm">Nevirapine</a></td><td class="cBV"><b>plasma concentration of  atazanavir possibly reduced by nevirapine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i673.htm">Norethisterone</a></td><td> atazanavir increases plasma concentration of norethisterone </td><td></td></tr><tr><td><a href="41001i1186.htm">Pazopanib</a></td><td class="cBV"><b>avoidance of  atazanavir advised by manufacturer of pazopanib </b></td><td></td></tr><tr><td><a href="41001i369.htm">Pimozide</a></td><td class="cBV"><b> atazanavir possibly increases plasma concentration of pimozide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1060.htm">Posaconazole</a></td><td class="cBV"><b>plasma concentration of  atazanavir increased by posaconazole </b></td><td></td></tr><tr><td><a href="41001i751.htm">Proton Pump Inhibitors</a></td><td class="cBV"><b>plasma concentration of  atazanavir reduced by proton pump inhibitors—avoid or adjust dose of both drugs (consult product literature)</b></td><td></td></tr><tr><td><a href="41001i824.htm">Quetiapine</a></td><td class="cBV"><b> atazanavir possibly increases plasma concentration of quetiapine—manufacturer of quetiapine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i341.htm">Quinine</a></td><td class="cBV"><b> atazanavir possibly increases plasma concentration of quinine (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i1147.htm">Ranolazine</a></td><td class="cBV"><b> atazanavir possibly increases plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i200.htm">Rifabutin</a></td><td class="cBV"><b> atazanavir increases plasma concentration of rifabutin (reduce dose of rifabutin)</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>plasma concentration of  atazanavir reduced by rifampicin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1136.htm">Rivaroxaban</a></td><td>avoidance of  atazanavir advised by manufacturer of rivaroxaban </td><td></td></tr><tr><td><a href="41001i974.htm">Rosuvastatin</a></td><td class="cBV"><b>possible increased risk of myopathy when  atazanavir given with rosuvastatin—manufacturer of rosuvastatin advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  atazanavir given with saquinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i858.htm">Sildenafil</a></td><td class="cBV"><b> atazanavir possibly increases side-effects of sildenafil </b></td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td class="cBV"><b>increased risk of myopathy when  atazanavir given with simvastatin (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i921.htm">Sirolimus</a></td><td class="cBV"><b> atazanavir possibly increases plasma concentration of sirolimus </b></td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>plasma concentration of  atazanavir reduced by St John's wort—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td class="cBV"><b> atazanavir possibly increases plasma concentration of tacrolimus </b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td> atazanavir possibly reduces plasma concentration of telaprevir , also plasma concentration of atazanavir possibly increased</td><td></td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td class="cBV"><b>avoidance of concomitant  atazanavir in severe renal and hepatic impairment advised by manufacturer of telithromycin </b></td><td></td></tr><tr><td><a href="41001i954.htm">Tenofovir</a></td><td>plasma concentration of  atazanavir reduced by tenofovir , also plasma concentration of tenofovir possibly increased</td><td></td></tr><tr><td><a href="41001i1203.htm">Ticagrelor</a></td><td class="cBV"><b> atazanavir possibly increases plasma concentration of ticagrelor—manufacturer of ticagrelor advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1055.htm">Tipranavir</a></td><td> atazanavir increases plasma concentration of tipranavir (also plasma concentration of atazanavir reduced)</td><td></td></tr><tr><td><a href="41001i467.htm">Verapamil</a></td><td> atazanavir possibly increases plasma concentration of verapamil </td><td></td></tr><tr><td><a href="41001i222.htm">Warfarin</a></td><td> atazanavir may enhance or reduce anticoagulant effect of warfarin </td><td></td></tr></tbody></table><p><b>Emtricitabine</b> belongs to
      <b>Antivirals</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i399.htm">Lamivudine</a></td><td>manufacturer of  emtricitabine advises avoid concomitant use with lamivudine </td><td></td></tr></tbody></table><p><b>Tenofovir</b> belongs to
      <b>Antivirals</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>






<tr><td><a href="41001i1088.htm">Adefovir</a></td><td>manufacturer of  tenofovir advises avoid concomitant use with adefovir </td><td></td></tr><tr><td><a href="41001i1005.htm">Atazanavir</a></td><td> tenofovir reduces plasma concentration of atazanavir , also plasma concentration of tenofovir possibly increased</td><td></td></tr><tr><td><a href="41001i951.htm">Cidofovir</a></td><td class="cBV"><b>manufacturers advise avoid concomitant use of  tenofovir with cidofovir </b></td><td></td></tr><tr><td><a href="41001i397.htm">Didanosine</a></td><td class="cBV"><b> tenofovir increases plasma concentration of didanosine (increased risk of toxicity)—avoid concomitant use</b></td><td>Antacids in tablet formulation may affect absorption of other drugs</td></tr><tr><td><a href="41001i922.htm">Lopinavir</a></td><td>plasma concentration of  tenofovir increased by lopinavir </td><td>In combination with ritonavir as <i>Kaletra</i>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td>plasma concentration of  tenofovir increased by telaprevir </td><td></td></tr></tbody></table><p><b>Ribavirin</b> belongs to
      <b>Antivirals</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>





<tr><td><a href="41001i907.htm">Abacavir</a></td><td class="cBV"><b>effects of  ribavirin possibly reduced by abacavir </b></td><td></td></tr><tr><td><a href="41001i519.htm">Azathioprine</a></td><td class="cBV"><b> ribavirin possibly enhances myelosuppressive effects of azathioprine </b></td><td></td></tr><tr><td><a href="41001i397.htm">Didanosine</a></td><td class="cBV"><b>increased risk of side-effects when  ribavirin given with didanosine—avoid concomitant use</b></td><td>Antacids in tablet formulation may affect absorption of other drugs</td></tr><tr><td><a href="41001i401.htm">Stavudine</a></td><td class="cBV"><b>increased risk of toxicity when  ribavirin given with stavudine </b></td><td></td></tr><tr><td><a href="41001i403.htm">Zidovudine</a></td><td class="cBV"><b>increased risk of anaemia when  ribavirin given with zidovudine—avoid concomitant use</b></td><td>Increased risk of toxicity with nephrotoxic and myelosuppressive drugs—for further details consult product literature</td></tr></tbody></table><p><b>Foscarnet</b> belongs to
      <b>Antivirals</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i808.htm">Pentamidine Isetionate</a></td><td class="cBV"><b>increased risk of hypocalcaemia when  foscarnet given with <i>parenteral</i> pentamidine isetionate </b></td><td></td></tr></tbody></table><p><b>Cidofovir</b> belongs to
      <b>Antivirals</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i954.htm">Tenofovir</a></td><td class="cBV"><b>manufacturers advise avoid concomitant use of  cidofovir with tenofovir </b></td><td></td></tr></tbody></table><p><b>Abacavir</b> belongs to
      <b>Antivirals</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>






<tr><td><a href="41001i97.htm">Methadone</a></td><td> abacavir possibly reduces plasma concentration of methadone </td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td>plasma concentration of  abacavir possibly reduced by phenobarbital </td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td>plasma concentration of  abacavir possibly reduced by phenytoin </td><td></td></tr><tr><td><a href="41001i953.htm">Ribavirin</a></td><td class="cBV"><b> abacavir possibly reduces effects of ribavirin </b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>plasma concentration of  abacavir possibly reduced by rifampicin </td><td></td></tr><tr><td><a href="41001i1055.htm">Tipranavir</a></td><td class="cBV"><b>plasma concentration of  abacavir reduced by tipranavir </b></td><td></td></tr></tbody></table><p><b>Aciclovir</b> belongs to
      <b>Antivirals</b>
          and has the following interaction information:
        </p><div>Interactions do not apply to topical aciclovir preparations</div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>





<tr><td><a href="41001i499.htm">Ciclosporin</a></td><td>increased risk of nephrotoxicity when  aciclovir given with ciclosporin </td><td></td></tr><tr><td><a href="41001i520.htm">Mycophenolate</a></td><td>plasma concentration of  aciclovir increased by mycophenolate , also plasma concentration of inactive metabolite of mycophenolate increased</td><td></td></tr><tr><td><a href="41001i663.htm">Probenecid</a></td><td>excretion of  aciclovir reduced by probenecid (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td>possible increased risk of nephrotoxicity when  aciclovir given with tacrolimus </td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i734.htm">Theophylline</a></td><td> aciclovir possibly increases plasma concentration of theophylline </td><td></td></tr></tbody></table><p><b>Valaciclovir</b> belongs to
      <b>Antivirals</b>
          but has no specific interaction information.
        </p><div>Valaciclovir interactions as for aciclovir</div><p><b>Didanosine</b> belongs to
      <b>Antivirals</b>
          and has the following interaction information:
        </p><div>Antacids in tablet formulation may affect absorption of other drugs</div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>








<tr><td><a href="41001i22.htm">Allopurinol</a></td><td class="cBV"><b>plasma concentration of  didanosine increased by allopurinol (risk of toxicity)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i395.htm">Ganciclovir</a></td><td>plasma concentration of  didanosine possibly increased by ganciclovir </td><td>Increased risk of myelosuppression with other myelosuppressive drugs—consult product literature</td></tr><tr><td><a href="41001i1052.htm">Hydroxycarbamide</a></td><td class="cBV"><b>increased risk of toxicity when  didanosine given with hydroxycarbamide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i97.htm">Methadone</a></td><td>plasma concentration of  didanosine possibly reduced by methadone </td><td></td></tr><tr><td><a href="41001i953.htm">Ribavirin</a></td><td class="cBV"><b>increased risk of side-effects when  didanosine given with ribavirin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i401.htm">Stavudine</a></td><td class="cBV"><b>increased risk of side-effects when  didanosine given with stavudine </b></td><td></td></tr><tr><td><a href="41001i954.htm">Tenofovir</a></td><td class="cBV"><b>plasma concentration of  didanosine increased by tenofovir (increased risk of toxicity)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1055.htm">Tipranavir</a></td><td class="cBV"><b>plasma concentration of  didanosine reduced by tipranavir </b></td><td></td></tr></tbody></table><p><b>Efavirenz</b> belongs to
      <b>Antivirals</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>




































<tr><td><a href="41001i1011.htm">Aripiprazole</a></td><td class="cBV"><b> efavirenz possibly reduces plasma concentration of aripiprazole—increase dose of aripiprazole</b></td><td></td></tr><tr><td><a href="41001i1005.htm">Atazanavir</a></td><td class="cBV"><b>avoidance of  efavirenz advised by manufacturer of atazanavir (plasma concentration of atazanavir reduced)</b></td><td></td></tr><tr><td><a href="41001i601.htm">Atorvastatin</a></td><td> efavirenz reduces plasma concentration of atorvastatin </td><td></td></tr><tr><td><a href="41001i431.htm">Atovaquone</a></td><td class="cBV"><b>avoidance of  efavirenz advised by manufacturer of atovaquone </b></td><td></td></tr><tr><td><a href="41001i896.htm">Bupropion</a></td><td> efavirenz accelerates metabolism of bupropion (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td>plasma concentration of both drugs reduced when  efavirenz given with carbamazepine </td><td></td></tr><tr><td><a href="41001i947.htm">Caspofungin</a></td><td> efavirenz possibly reduces plasma concentration of caspofungin—consider increasing dose of caspofungin</td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b> efavirenz possibly reduces plasma concentration of ciclosporin </b></td><td></td></tr><tr><td><a href="41001i168.htm">Clarithromycin</a></td><td>increased risk of rash when  efavirenz given with clarithromycin </td><td></td></tr><tr><td><a href="41001i1091.htm">Darunavir</a></td><td> efavirenz reduces plasma concentration of darunavir </td><td></td></tr><tr><td><a href="41001i468.htm">Diltiazem</a></td><td> efavirenz reduces plasma concentration of diltiazem </td><td></td></tr><tr><td><a href="41001i981.htm">Ergot Alkaloids</a></td><td class="cBV"><b>increased risk of ergotism when  efavirenz given with ergot alkaloids—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1135.htm">Etravirine</a></td><td class="cBV"><b> efavirenz possibly reduces plasma concentration of etravirine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1019.htm">Fosamprenavir</a></td><td> efavirenz reduces plasma concentration of fosamprenavir </td><td>Fosamprenavir is a prodrug of amprenavir</td></tr><tr><td><a href="41001i829.htm">Grapefruit Juice</a></td><td>plasma concentration of  efavirenz possibly increased by grapefruit juice </td><td></td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td> efavirenz reduces plasma concentration of indinavir </td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td> efavirenz reduces plasma concentration of itraconazole </td><td></td></tr><tr><td><a href="41001i922.htm">Lopinavir</a></td><td class="cBV"><b> efavirenz reduces plasma concentration of lopinavir—consider increasing dose of lopinavir</b></td><td>In combination with ritonavir as <i>Kaletra</i>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</td></tr><tr><td><a href="41001i1107.htm">Maraviroc</a></td><td class="cBV"><b> efavirenz possibly reduces plasma concentration of maraviroc—consider increasing dose of maraviroc</b></td><td></td></tr><tr><td><a href="41001i97.htm">Methadone</a></td><td> efavirenz reduces plasma concentration of methadone </td><td></td></tr><tr><td><a href="41001i421.htm">Midazolam</a></td><td class="cBV"><b>increased risk of prolonged sedation when  efavirenz given with midazolam—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i843.htm">Nevirapine</a></td><td>plasma concentration of  efavirenz reduced by nevirapine </td><td></td></tr><tr><td><a href="41001i369.htm">Pimozide</a></td><td class="cBV"><b> efavirenz possibly increases plasma concentration of pimozide (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i1060.htm">Posaconazole</a></td><td class="cBV"><b> efavirenz reduces plasma concentration of posaconazole </b></td><td></td></tr><tr><td><a href="41001i604.htm">Pravastatin</a></td><td> efavirenz reduces plasma concentration of pravastatin </td><td></td></tr><tr><td><a href="41001i664.htm">Progestogens</a></td><td class="cBV"><b> efavirenz possibly reduces contraceptive effect of progestogens </b></td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="" href="4552.htm#_120026">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a title="" href="4572.htm#_4572.2">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a title="" href="4580.htm#_4580.4">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a title="" href="31947.htm#_31947.1">section 7.3.2.3</a>; hormonal emergency contraception, see also <a title="" href="130057.htm#_100043.3">section 7.3.5</a></td></tr><tr><td><a href="41001i200.htm">Rifabutin</a></td><td> efavirenz reduces plasma concentration of rifabutin—increase dose of rifabutin</td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>plasma concentration of  efavirenz reduced by rifampicin—increase dose of efavirenz</td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td>toxicity of  efavirenz increased by ritonavir , monitor liver function tests</td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td> efavirenz significantly reduces plasma concentration of saquinavir </td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td> efavirenz reduces plasma concentration of simvastatin </td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>plasma concentration of  efavirenz reduced by St John's wort—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td class="cBV"><b> efavirenz possibly affects plasma concentration of tacrolimus </b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td class="cBV"><b> efavirenz reduces plasma concentration of telaprevir—increase dose of telaprevir</b></td><td></td></tr><tr><td><a href="41001i948.htm">Voriconazole</a></td><td class="cBV"><b> efavirenz reduces plasma concentration of voriconazole , also plasma concentration of efavirenz increased (increase voriconazole dose and reduce efavirenz dose)</b></td><td></td></tr><tr><td><a href="41001i222.htm">Warfarin</a></td><td class="cBV"><b> efavirenz possibly affects plasma concentration of warfarin </b></td><td></td></tr></tbody></table><p><b>Famciclovir</b> belongs to
      <b>Antivirals</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i663.htm">Probenecid</a></td><td>excretion of  famciclovir possibly reduced by probenecid (increased plasma concentration)</td><td></td></tr></tbody></table><p><b>Ganciclovir</b> belongs to
      <b>Antivirals</b>
          and has the following interaction information:
        </p><div>Increased risk of myelosuppression with other myelosuppressive drugs—consult product literature</div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>






<tr><td><a href="41001i397.htm">Didanosine</a></td><td> ganciclovir possibly increases plasma concentration of didanosine </td><td>Antacids in tablet formulation may affect absorption of other drugs</td></tr><tr><td><a href="41001i139.htm">Imipenem with Cilastatin</a></td><td class="cBV"><b>increased risk of convulsions when  ganciclovir given with imipenem with cilastatin </b></td><td></td></tr><tr><td><a href="41001i520.htm">Mycophenolate</a></td><td>plasma concentration of  ganciclovir possibly increased by mycophenolate , also plasma concentration of inactive metabolite of mycophenolate possibly increased</td><td></td></tr><tr><td><a href="41001i663.htm">Probenecid</a></td><td>excretion of  ganciclovir reduced by probenecid (increased plasma concentration and risk of toxicity)</td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td>possible increased risk of nephrotoxicity when  ganciclovir given with tacrolimus </td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i403.htm">Zidovudine</a></td><td class="cBV"><b>profound myelosuppression when  ganciclovir given with zidovudine (if possible avoid concomitant administration, particularly during initial ganciclovir therapy)</b></td><td>Increased risk of toxicity with nephrotoxic and myelosuppressive drugs—for further details consult product literature</td></tr></tbody></table><p><b>Valganciclovir</b> belongs to
      <b>Antivirals</b>
          but has no specific interaction information.
        </p><div>Valganciclovir interactions as for ganciclovir</div><p><b>Indinavir</b> belongs to
      <b>Antivirals</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

















































<tr><td><a href="41001i21.htm">Aldesleukin</a></td><td>plasma concentration of  indinavir possibly increased by aldesleukin </td><td></td></tr><tr><td><a href="41001i406.htm">Alprazolam</a></td><td class="cBV"><b>increased risk of prolonged sedation when  indinavir given with alprazolam—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i118.htm">Amiodarone</a></td><td class="cBV"><b> indinavir possibly increases plasma concentration of amiodarone—avoid concomitant use</b></td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i1217.htm">Apixaban</a></td><td>avoidance of  indinavir advised by manufacturer of apixaban </td><td></td></tr><tr><td><a href="41001i1011.htm">Aripiprazole</a></td><td class="cBV"><b> indinavir possibly inhibits metabolism of aripiprazole (reduce dose of aripiprazole)</b></td><td></td></tr><tr><td><a href="41001i937.htm">Artemether with Lumefantrine</a></td><td>caution with  indinavir advised by manufacturer of artemether/lumefantrine </td><td></td></tr><tr><td><a href="41001i1005.htm">Atazanavir</a></td><td class="cBV"><b>avoid concomitant use of  indinavir with atazanavir </b></td><td></td></tr><tr><td><a href="41001i601.htm">Atorvastatin</a></td><td>possible increased risk of myopathy when  indinavir given with atorvastatin </td><td></td></tr><tr><td><a href="41001i431.htm">Atovaquone</a></td><td>plasma concentration of  indinavir possibly reduced by atovaquone </td><td></td></tr><tr><td><a href="41001i1204.htm">Cabazitaxel</a></td><td class="cBV"><b>avoidance of  indinavir advised by manufacturer of cabazitaxel </b></td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td class="cBV"><b>plasma concentration of  indinavir possibly reduced by carbamazepine , also plasma concentration of carbamazepine possibly increased</b></td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b> indinavir increases plasma concentration of ciclosporin </b></td><td></td></tr><tr><td><a href="41001i483.htm">Colchicine</a></td><td class="cBV"><b> indinavir possibly increases risk of colchicine toxicity—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)</b></td><td></td></tr><tr><td><a href="41001i1076.htm">Darifenacin</a></td><td>avoidance of  indinavir advised by manufacturer of darifenacin </td><td></td></tr><tr><td><a href="41001i1091.htm">Darunavir</a></td><td>plasma concentration of both drugs increased when  indinavir given with darunavir </td><td></td></tr><tr><td><a href="41001i490.htm">Dexamethasone</a></td><td>plasma concentration of  indinavir possibly reduced by dexamethasone </td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td>plasma concentration of  indinavir reduced by efavirenz </td><td></td></tr><tr><td><a href="41001i963.htm">Eletriptan</a></td><td class="cBV"><b> indinavir increases plasma concentration of eletriptan (risk of toxicity)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i563.htm">Ergotamine and Methysergide</a></td><td class="cBV"><b>increased risk of ergotism when  indinavir given with ergotamine and methysergide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1135.htm">Etravirine</a></td><td class="cBV"><b>plasma concentration of  indinavir possibly reduced by etravirine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1169.htm">Everolimus</a></td><td class="cBV"><b> indinavir possibly increases plasma concentration of everolimus—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1119.htm">Fesoterodine</a></td><td>manufacturer of fesoterodine advises dose reduction when  indinavir given with fesoterodine—consult fesoterodine product literature</td><td></td></tr><tr><td><a href="41001i120.htm">Flecainide</a></td><td class="cBV"><b> indinavir possibly increases plasma concentration of flecainide (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td class="cBV"><b>plasma concentration of  indinavir increased by itraconazole (consider reducing dose of indinavir)</b></td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td class="cBV"><b>plasma concentration of  indinavir increased by ketoconazole (consider reducing dose of indinavir)</b></td><td></td></tr><tr><td><a href="41001i1107.htm">Maraviroc</a></td><td class="cBV"><b> indinavir increases plasma concentration of maraviroc (consider reducing dose of maraviroc)</b></td><td></td></tr><tr><td><a href="41001i421.htm">Midazolam</a></td><td class="cBV"><b> indinavir possibly increases plasma concentration of midazolam (risk of prolonged sedation—avoid concomitant use of <i>oral</i> midazolam)</b></td><td></td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td>combination of  indinavir with nelfinavir may increase plasma concentration of either drug (or both)</td><td></td></tr><tr><td><a href="41001i843.htm">Nevirapine</a></td><td>plasma concentration of  indinavir reduced by nevirapine </td><td></td></tr><tr><td><a href="41001i1186.htm">Pazopanib</a></td><td class="cBV"><b>avoidance of  indinavir advised by manufacturer of pazopanib </b></td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td class="cBV"><b>plasma concentration of  indinavir possibly reduced by phenobarbital </b></td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b>plasma concentration of  indinavir possibly reduced by phenytoin , also plasma concentration of phenytoin possibly increased</b></td><td></td></tr><tr><td><a href="41001i369.htm">Pimozide</a></td><td class="cBV"><b> indinavir possibly increases plasma concentration of pimozide (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i824.htm">Quetiapine</a></td><td class="cBV"><b> indinavir possibly increases plasma concentration of quetiapine—manufacturer of quetiapine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i341.htm">Quinine</a></td><td class="cBV"><b> indinavir possibly increases plasma concentration of quinine (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i1147.htm">Ranolazine</a></td><td class="cBV"><b> indinavir possibly increases plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i200.htm">Rifabutin</a></td><td class="cBV"><b> indinavir increases plasma concentration of rifabutin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>metabolism of  indinavir accelerated by rifampicin (reduced plasma concentration—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td>plasma concentration of  indinavir increased by ritonavir </td><td></td></tr><tr><td><a href="41001i1136.htm">Rivaroxaban</a></td><td>avoidance of  indinavir advised by manufacturer of rivaroxaban </td><td></td></tr><tr><td><a href="41001i974.htm">Rosuvastatin</a></td><td class="cBV"><b>possible increased risk of myopathy when  indinavir given with rosuvastatin—manufacturer of rosuvastatin advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td> indinavir increases plasma concentration of saquinavir </td><td></td></tr><tr><td><a href="41001i858.htm">Sildenafil</a></td><td class="cBV"><b> indinavir increases plasma concentration of sildenafil—reduce initial dose of sildenafil</b></td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td class="cBV"><b>increased risk of myopathy when  indinavir given with simvastatin (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>plasma concentration of  indinavir reduced by St John's wort—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i945.htm">Tadalafil</a></td><td> indinavir possibly increases plasma concentration of tadalafil </td><td></td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td class="cBV"><b>avoidance of concomitant  indinavir in severe renal and hepatic impairment advised by manufacturer of telithromycin </b></td><td></td></tr><tr><td><a href="41001i850.htm">Tolterodine</a></td><td>avoidance of  indinavir advised by manufacturer of tolterodine </td><td></td></tr><tr><td><a href="41001i967.htm">Vardenafil</a></td><td class="cBV"><b> indinavir increases plasma concentration of vardenafil—avoid concomitant use</b></td><td></td></tr></tbody></table><p><b>Lamivudine</b> belongs to
      <b>Antivirals</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i998.htm">Emtricitabine</a></td><td>avoidance of  lamivudine advised by manufacturer of emtricitabine </td><td></td></tr><tr><td><a href="41001i217.htm">Trimethoprim</a></td><td>plasma concentration of  lamivudine increased by trimethoprim (as co-trimoxazole)—avoid concomitant use of high-dose co-trimoxazole</td><td></td></tr></tbody></table><p><b>Lopinavir</b> belongs to
      <b>Antivirals</b>
          and has the following interaction information:
        </p><div>In combination with ritonavir as <i>Kaletra</i>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

































<tr><td><a href="41001i1217.htm">Apixaban</a></td><td>avoidance of  lopinavir advised by manufacturer of apixaban </td><td></td></tr><tr><td><a href="41001i1011.htm">Aripiprazole</a></td><td class="cBV"><b> lopinavir possibly inhibits metabolism of aripiprazole (reduce dose of aripiprazole)</b></td><td></td></tr><tr><td><a href="41001i937.htm">Artemether with Lumefantrine</a></td><td>caution with  lopinavir advised by manufacturer of artemether/lumefantrine </td><td></td></tr><tr><td><a href="41001i601.htm">Atorvastatin</a></td><td>possible increased risk of myopathy when  lopinavir given with atorvastatin </td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td>plasma concentration of  lopinavir possibly reduced by carbamazepine </td><td></td></tr><tr><td><a href="41001i315.htm">Chlorphenamine</a></td><td> lopinavir possibly increases plasma concentration of chlorphenamine </td><td></td></tr><tr><td><a href="41001i1076.htm">Darifenacin</a></td><td>avoidance of  lopinavir advised by manufacturer of darifenacin </td><td></td></tr><tr><td><a href="41001i1091.htm">Darunavir</a></td><td class="cBV"><b> lopinavir reduces plasma concentration of darunavir , also plasma concentration of lopinavir increased (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i490.htm">Dexamethasone</a></td><td>plasma concentration of  lopinavir possibly reduced by dexamethasone </td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td class="cBV"><b>plasma concentration of  lopinavir reduced by efavirenz—consider increasing dose of lopinavir</b></td><td></td></tr><tr><td><a href="41001i1177.htm">Eltrombopag</a></td><td> lopinavir possibly reduces plasma concentration of eltrombopag </td><td></td></tr><tr><td><a href="41001i120.htm">Flecainide</a></td><td class="cBV"><b> lopinavir possibly increases plasma concentration of flecainide (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i1019.htm">Fosamprenavir</a></td><td> lopinavir reduces plasma concentration of fosamprenavir , effect on lopinavir plasma concentration not predictable—avoid concomitant use</td><td>Fosamprenavir is a prodrug of amprenavir</td></tr><tr><td><a href="41001i55.htm">Lidocaine</a></td><td> lopinavir possibly increases plasma concentration of lidocaine </td><td>Interactions less likely when lidocaine used topically</td></tr><tr><td><a href="41001i1107.htm">Maraviroc</a></td><td class="cBV"><b> lopinavir increases plasma concentration of maraviroc (consider reducing dose of maraviroc)</b></td><td></td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td>plasma concentration of  lopinavir reduced by nelfinavir , also plasma concentration of active metabolite of nelfinavir increased</td><td></td></tr><tr><td><a href="41001i843.htm">Nevirapine</a></td><td class="cBV"><b>plasma concentration of  lopinavir possibly reduced by nevirapine—consider increasing dose of lopinavir</b></td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td class="cBV"><b>plasma concentration of  lopinavir possibly reduced by phenobarbital </b></td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td>plasma concentration of  lopinavir possibly reduced by phenytoin </td><td></td></tr><tr><td><a href="41001i824.htm">Quetiapine</a></td><td class="cBV"><b> lopinavir possibly increases plasma concentration of quetiapine—manufacturer of quetiapine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1147.htm">Ranolazine</a></td><td class="cBV"><b> lopinavir possibly increases plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>plasma concentration of  lopinavir reduced by rifampicin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1136.htm">Rivaroxaban</a></td><td>avoidance of  lopinavir advised by manufacturer of rivaroxaban </td><td></td></tr><tr><td><a href="41001i974.htm">Rosuvastatin</a></td><td class="cBV"><b>possible increased risk of myopathy when  lopinavir given with rosuvastatin—manufacturer of rosuvastatin advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  lopinavir given with saquinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td class="cBV"><b>possible increased risk of myopathy when  lopinavir given with simvastatin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i921.htm">Sirolimus</a></td><td> lopinavir possibly increases plasma concentration of sirolimus </td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>plasma concentration of  lopinavir reduced by St John's wort—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td class="cBV"><b>avoidance of  lopinavir advised by manufacturer of telaprevir </b></td><td></td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td class="cBV"><b>avoidance of concomitant  lopinavir in severe renal and hepatic impairment advised by manufacturer of telithromycin </b></td><td></td></tr><tr><td><a href="41001i954.htm">Tenofovir</a></td><td> lopinavir increases plasma concentration of tenofovir </td><td></td></tr><tr><td><a href="41001i1055.htm">Tipranavir</a></td><td class="cBV"><b>plasma concentration of  lopinavir reduced by tipranavir </b></td><td></td></tr><tr><td><a href="41001i850.htm">Tolterodine</a></td><td>avoidance of  lopinavir advised by manufacturer of tolterodine </td><td></td></tr></tbody></table><p><b>Nelfinavir</b> belongs to
      <b>Antivirals</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>






















































<tr><td><a href="41001i30.htm">Alfuzosin</a></td><td>manufacturer of  nelfinavir advises avoid concomitant use with alfuzosin </td><td></td></tr><tr><td><a href="41001i118.htm">Amiodarone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  nelfinavir given with amiodarone—avoid concomitant use</b></td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i1217.htm">Apixaban</a></td><td>avoidance of  nelfinavir advised by manufacturer of apixaban </td><td></td></tr><tr><td><a href="41001i1011.htm">Aripiprazole</a></td><td class="cBV"><b> nelfinavir possibly inhibits metabolism of aripiprazole (reduce dose of aripiprazole)</b></td><td></td></tr><tr><td><a href="41001i937.htm">Artemether with Lumefantrine</a></td><td>caution with  nelfinavir advised by manufacturer of artemether/lumefantrine </td><td></td></tr><tr><td><a href="41001i601.htm">Atorvastatin</a></td><td>possible increased risk of myopathy when  nelfinavir given with atorvastatin </td><td></td></tr><tr><td><a href="41001i167.htm">Azithromycin</a></td><td> nelfinavir increases plasma concentration of azithromycin (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i496.htm">Budesonide</a></td><td> nelfinavir possibly increases plasma concentration of budesonide (including <i>inhaled</i> and <i>intranasal</i> budesonide)</td><td></td></tr><tr><td><a href="41001i1204.htm">Cabazitaxel</a></td><td class="cBV"><b>avoidance of  nelfinavir advised by manufacturer of cabazitaxel </b></td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td>plasma concentration of  nelfinavir possibly reduced by carbamazepine </td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b> nelfinavir possibly increases plasma concentration of ciclosporin </b></td><td></td></tr><tr><td><a href="41001i483.htm">Colchicine</a></td><td class="cBV"><b> nelfinavir possibly increases risk of colchicine toxicity—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)</b></td><td></td></tr><tr><td><a href="41001i1076.htm">Darifenacin</a></td><td>avoidance of  nelfinavir advised by manufacturer of darifenacin </td><td></td></tr><tr><td><a href="41001i963.htm">Eletriptan</a></td><td class="cBV"><b> nelfinavir increases plasma concentration of eletriptan (risk of toxicity)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1025.htm">Eplerenone</a></td><td class="cBV"><b> nelfinavir increases plasma concentration of eplerenone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i563.htm">Ergotamine and Methysergide</a></td><td class="cBV"><b>increased risk of ergotism when  nelfinavir given with ergotamine and methysergide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i914.htm">Esomeprazole</a></td><td class="cBV"><b>plasma concentration of  nelfinavir possibly reduced by esomeprazole—manufacturer of esomeprazole advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1135.htm">Etravirine</a></td><td>plasma concentration of  nelfinavir possibly increased by etravirine—avoid concomitant use</td><td></td></tr><tr><td><a href="41001i1169.htm">Everolimus</a></td><td class="cBV"><b> nelfinavir possibly increases plasma concentration of everolimus—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1119.htm">Fesoterodine</a></td><td>manufacturer of fesoterodine advises dose reduction when  nelfinavir given with fesoterodine—consult fesoterodine product literature</td><td></td></tr><tr><td><a href="41001i497.htm">Fluticasone</a></td><td> nelfinavir possibly increases plasma concentration of <i>inhaled</i> and <i>intranasal</i> fluticasone </td><td></td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td>combination of  nelfinavir with indinavir may increase plasma concentration of either drug (or both)</td><td></td></tr><tr><td><a href="41001i1050.htm">Ivabradine</a></td><td class="cBV"><b> nelfinavir possibly increases plasma concentration of ivabradine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i922.htm">Lopinavir</a></td><td> nelfinavir reduces plasma concentration of lopinavir , also plasma concentration of active metabolite of nelfinavir increased</td><td>In combination with ritonavir as <i>Kaletra</i>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</td></tr><tr><td><a href="41001i1107.htm">Maraviroc</a></td><td class="cBV"><b> nelfinavir possibly increases plasma concentration of maraviroc (consider reducing dose of maraviroc)</b></td><td></td></tr><tr><td><a href="41001i97.htm">Methadone</a></td><td> nelfinavir reduces plasma concentration of methadone </td><td></td></tr><tr><td><a href="41001i421.htm">Midazolam</a></td><td class="cBV"><b> nelfinavir possibly increases plasma concentration of midazolam (risk of prolonged sedation—avoid concomitant use of <i>oral</i> midazolam)</b></td><td></td></tr><tr><td><a href="41001i636.htm">Oestrogens</a></td><td class="cBV"><b> nelfinavir accelerates metabolism of oestrogens (reduced contraceptive effect—see <a title="target-block: COCs interactions" href="4552.htm#_120026">section 7.3.1</a>)</b></td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="4552.htm#_120026">section 7.3.1</a></td></tr><tr><td><a href="41001i752.htm">Omeprazole</a></td><td class="cBV"><b>plasma concentration of  nelfinavir reduced by omeprazole—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i517.htm">Paclitaxel</a></td><td> nelfinavir increases plasma concentration of paclitaxel </td><td></td></tr><tr><td><a href="41001i1186.htm">Pazopanib</a></td><td class="cBV"><b>avoidance of  nelfinavir advised by manufacturer of pazopanib </b></td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td class="cBV"><b>plasma concentration of  nelfinavir possibly reduced by phenobarbital </b></td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td> nelfinavir reduces plasma concentration of phenytoin </td><td></td></tr><tr><td><a href="41001i369.htm">Pimozide</a></td><td class="cBV"><b> nelfinavir possibly increases plasma concentration of pimozide (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i664.htm">Progestogens</a></td><td> nelfinavir possibly reduces contraceptive effect of progestogens </td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="" href="4552.htm#_120026">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a title="" href="4572.htm#_4572.2">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a title="" href="4580.htm#_4580.4">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a title="" href="31947.htm#_31947.1">section 7.3.2.3</a>; hormonal emergency contraception, see also <a title="" href="130057.htm#_100043.3">section 7.3.5</a></td></tr><tr><td><a href="41001i824.htm">Quetiapine</a></td><td class="cBV"><b> nelfinavir possibly increases plasma concentration of quetiapine—manufacturer of quetiapine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i341.htm">Quinine</a></td><td class="cBV"><b> nelfinavir possibly increases plasma concentration of quinine (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i1147.htm">Ranolazine</a></td><td class="cBV"><b> nelfinavir possibly increases plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i200.htm">Rifabutin</a></td><td class="cBV"><b> nelfinavir increases plasma concentration of rifabutin (halve dose of rifabutin)</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>plasma concentration of  nelfinavir significantly reduced by rifampicin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td>combination of  nelfinavir with ritonavir may increase plasma concentration of either drug (or both)</td><td></td></tr><tr><td><a href="41001i1136.htm">Rivaroxaban</a></td><td>avoidance of  nelfinavir advised by manufacturer of rivaroxaban </td><td></td></tr><tr><td><a href="41001i974.htm">Rosuvastatin</a></td><td class="cBV"><b>possible increased risk of myopathy when  nelfinavir given with rosuvastatin—manufacturer of rosuvastatin advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i727.htm">Salmeterol</a></td><td>manufacturer of  nelfinavir advises avoid concomitant use with salmeterol </td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b> nelfinavir increases plasma concentration of saquinavir—manufacturer of saquinavir advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i858.htm">Sildenafil</a></td><td> nelfinavir possibly increases plasma concentration of sildenafil—reduce initial dose of sildenafil</td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td class="cBV"><b>increased risk of myopathy when  nelfinavir given with simvastatin (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i1020.htm">Solifenacin</a></td><td> nelfinavir increases plasma concentration of solifenacin </td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>plasma concentration of  nelfinavir reduced by St John's wort—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td class="cBV"><b> nelfinavir possibly increases plasma concentration of tacrolimus </b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i945.htm">Tadalafil</a></td><td>manufacturer of  nelfinavir advises caution with tadalafil </td><td></td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td class="cBV"><b>avoidance of concomitant  nelfinavir in severe renal and hepatic impairment advised by manufacturer of telithromycin </b></td><td></td></tr><tr><td><a href="41001i850.htm">Tolterodine</a></td><td>avoidance of  nelfinavir advised by manufacturer of tolterodine </td><td></td></tr><tr><td><a href="41001i967.htm">Vardenafil</a></td><td>manufacturer of  nelfinavir advises caution with vardenafil </td><td></td></tr></tbody></table><p><b>Nevirapine</b> belongs to
      <b>Antivirals</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>




















<tr><td><a href="41001i1011.htm">Aripiprazole</a></td><td class="cBV"><b> nevirapine possibly reduces plasma concentration of aripiprazole—increase dose of aripiprazole</b></td><td></td></tr><tr><td><a href="41001i1005.htm">Atazanavir</a></td><td class="cBV"><b> nevirapine possibly reduces plasma concentration of atazanavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td>plasma concentration of  nevirapine reduced by carbamazepine </td><td></td></tr><tr><td><a href="41001i947.htm">Caspofungin</a></td><td> nevirapine possibly reduces plasma concentration of caspofungin—consider increasing dose of caspofungin</td><td></td></tr><tr><td><a href="41001i168.htm">Clarithromycin</a></td><td> nevirapine reduces plasma concentration of clarithromycin (but concentration of an active metabolite increased), also plasma concentration of nevirapine increased</td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td> nevirapine reduces plasma concentration of efavirenz </td><td></td></tr><tr><td><a href="41001i1135.htm">Etravirine</a></td><td class="cBV"><b> nevirapine possibly reduces plasma concentration of etravirine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i301.htm">Fluconazole</a></td><td class="cBV"><b>plasma concentration of  nevirapine increased by fluconazole </b></td><td>In general, fluconazole interactions relate to multiple-dose treatment</td></tr><tr><td><a href="41001i1019.htm">Fosamprenavir</a></td><td> nevirapine possibly reduces plasma concentration of fosamprenavir </td><td>Fosamprenavir is a prodrug of amprenavir</td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td> nevirapine reduces plasma concentration of indinavir </td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td> nevirapine possibly reduces plasma concentration of itraconazole—consider increasing dose of itraconazole</td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td class="cBV"><b> nevirapine reduces plasma concentration of ketoconazole—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i922.htm">Lopinavir</a></td><td class="cBV"><b> nevirapine possibly reduces plasma concentration of lopinavir—consider increasing dose of lopinavir</b></td><td>In combination with ritonavir as <i>Kaletra</i>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</td></tr><tr><td><a href="41001i97.htm">Methadone</a></td><td> nevirapine possibly reduces plasma concentration of methadone </td><td></td></tr><tr><td><a href="41001i636.htm">Oestrogens</a></td><td class="cBV"><b> nevirapine accelerates metabolism of oestrogens (reduced contraceptive effect—see <a title="target-block: COCs interactions" href="4552.htm#_120026">section 7.3.1</a>)</b></td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="4552.htm#_120026">section 7.3.1</a></td></tr><tr><td><a href="41001i664.htm">Progestogens</a></td><td class="cBV"><b> nevirapine accelerates metabolism of progestogens (reduced contraceptive effect—see <a title="target-block: COCs interactions" href="4552.htm#_120026">section 7.3.1</a>)</b></td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="" href="4552.htm#_120026">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a title="" href="4572.htm#_4572.2">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a title="" href="4580.htm#_4580.4">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a title="" href="31947.htm#_31947.1">section 7.3.2.3</a>; hormonal emergency contraception, see also <a title="" href="130057.htm#_100043.3">section 7.3.5</a></td></tr><tr><td><a href="41001i200.htm">Rifabutin</a></td><td> nevirapine possibly increases plasma concentration of rifabutin </td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>plasma concentration of  nevirapine reduced by rifampicin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>plasma concentration of  nevirapine reduced by St John's wort—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i222.htm">Warfarin</a></td><td class="cBV"><b> nevirapine may enhance or reduce anticoagulant effect of warfarin </b></td><td></td></tr></tbody></table><p><b>Ritonavir</b> belongs to
      <b>Antivirals</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>









































































































<tr><td><a href="41001i86.htm">Alfentanil</a></td><td class="cBV"><b> ritonavir increases plasma concentration of alfentanil </b></td><td></td></tr><tr><td><a href="41001i30.htm">Alfuzosin</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of alfuzosin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i406.htm">Alprazolam</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of alprazolam (risk of extreme sedation and respiratory depression—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i118.htm">Amiodarone</a></td><td class="cBV"><b> ritonavir increases plasma concentration of amiodarone (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i232.htm">Antidepressants, SSRI</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of SSRIs </b></td><td></td></tr><tr><td><a href="41001i241.htm">Antidepressants, Tricyclic</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of tricyclics </b></td><td></td></tr><tr><td><a href="41001i304.htm">Antihistamines, Non-sedating</a></td><td> ritonavir possibly increases plasma concentration of non-sedating antihistamines </td><td></td></tr><tr><td><a href="41001i363.htm">Antipsychotics</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of antipsychotics </b></td><td>Increased risk of toxicity with myelosuppressive drugs</td></tr><tr><td><a href="41001i404.htm">Anxiolytics and Hypnotics</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of anxiolytics and hypnotics </b></td><td></td></tr><tr><td><a href="41001i1217.htm">Apixaban</a></td><td>avoidance of  ritonavir advised by manufacturer of apixaban </td><td></td></tr><tr><td><a href="41001i1010.htm">Aprepitant</a></td><td> ritonavir possibly increases plasma concentration of aprepitant </td><td></td></tr><tr><td><a href="41001i1011.htm">Aripiprazole</a></td><td class="cBV"><b> ritonavir possibly inhibits metabolism of aripiprazole (reduce dose of aripiprazole)</b></td><td></td></tr><tr><td><a href="41001i937.htm">Artemether with Lumefantrine</a></td><td>caution with  ritonavir advised by manufacturer of artemether/lumefantrine </td><td></td></tr><tr><td><a href="41001i601.htm">Atorvastatin</a></td><td>possible increased risk of myopathy when  ritonavir given with atorvastatin </td><td></td></tr><tr><td><a href="41001i167.htm">Azithromycin</a></td><td> ritonavir possibly increases plasma concentration of azithromycin </td><td></td></tr><tr><td><a href="41001i943.htm">Bosentan</a></td><td class="cBV"><b> ritonavir increases plasma concentration of bosentan </b></td><td></td></tr><tr><td><a href="41001i496.htm">Budesonide</a></td><td> ritonavir increases plasma concentration of <i>inhaled</i> and <i>intranasal</i> budesonide </td><td></td></tr><tr><td><a href="41001i87.htm">Buprenorphine</a></td><td> ritonavir possibly increases plasma concentration of buprenorphine </td><td></td></tr><tr><td><a href="41001i896.htm">Bupropion</a></td><td> ritonavir reduces plasma concentration of bupropion </td><td></td></tr><tr><td><a href="41001i427.htm">Buspirone</a></td><td> ritonavir increases plasma concentration of buspirone (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i1204.htm">Cabazitaxel</a></td><td class="cBV"><b>avoidance of  ritonavir advised by manufacturer of cabazitaxel </b></td><td></td></tr><tr><td><a href="41001i466.htm">Calcium-channel Blockers</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of calcium-channel blockers </b></td><td>Dihydropyridine calcium-channel blockers include amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine</td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of carbamazepine </b></td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of ciclosporin </b></td><td></td></tr><tr><td><a href="41001i168.htm">Clarithromycin</a></td><td class="cBV"><b> ritonavir increases plasma concentration of clarithromycin (reduce dose of clarithromycin in renal impairment)</b></td><td></td></tr><tr><td><a href="41001i364.htm">Clozapine</a></td><td class="cBV"><b> ritonavir increases plasma concentration of clozapine (increased risk of toxicity)—avoid concomitant use</b></td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr><tr><td><a href="41001i483.htm">Colchicine</a></td><td class="cBV"><b> ritonavir possibly increases risk of colchicine toxicity—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)</b></td><td></td></tr><tr><td><a href="41001i484.htm">Corticosteroids</a></td><td> ritonavir possibly increases plasma concentration of corticosteroids </td><td>Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> ritonavir possibly enhances anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i1076.htm">Darifenacin</a></td><td>avoidance of  ritonavir advised by manufacturer of darifenacin </td><td></td></tr><tr><td><a href="41001i490.htm">Dexamethasone</a></td><td> ritonavir possibly increases plasma concentration of dexamethasone </td><td></td></tr><tr><td><a href="41001i714.htm">Dexamfetamine</a></td><td> ritonavir possibly increases plasma concentration of dexamfetamine </td><td></td></tr><tr><td><a href="41001i90.htm">Dextropropoxyphene</a></td><td class="cBV"><b> ritonavir increases plasma concentration of dextropropoxyphene (risk of toxicity)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i412.htm">Diazepam</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of diazepam (risk of extreme sedation and respiratory depression—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i480.htm">Digoxin</a></td><td> ritonavir possibly increases plasma concentration of digoxin </td><td></td></tr><tr><td><a href="41001i119.htm">Disopyramide</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of disopyramide (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i516.htm">Docetaxel</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of docetaxel (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i1176.htm">Dronedarone</a></td><td class="cBV"><b>avoidance of  ritonavir advised by manufacturer of dronedarone </b></td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td> ritonavir increases toxicity of efavirenz , monitor liver function tests</td><td></td></tr><tr><td><a href="41001i963.htm">Eletriptan</a></td><td class="cBV"><b> ritonavir increases plasma concentration of eletriptan (risk of toxicity)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1025.htm">Eplerenone</a></td><td class="cBV"><b> ritonavir increases plasma concentration of eplerenone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i563.htm">Ergotamine and Methysergide</a></td><td class="cBV"><b>increased risk of ergotism when  ritonavir given with ergotamine and methysergide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i169.htm">Erythromycin</a></td><td> ritonavir possibly increases plasma concentration of erythromycin </td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i1169.htm">Everolimus</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of everolimus—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i95.htm">Fentanyl</a></td><td class="cBV"><b> ritonavir increases plasma concentration of fentanyl </b></td><td></td></tr><tr><td><a href="41001i1119.htm">Fesoterodine</a></td><td>manufacturer of fesoterodine advises dose reduction when  ritonavir given with fesoterodine—consult fesoterodine product literature</td><td></td></tr><tr><td><a href="41001i120.htm">Flecainide</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of flecainide (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i301.htm">Fluconazole</a></td><td>plasma concentration of  ritonavir increased by fluconazole </td><td>In general, fluconazole interactions relate to multiple-dose treatment</td></tr><tr><td><a href="41001i416.htm">Flurazepam</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of flurazepam (risk of extreme sedation and respiratory depression—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i497.htm">Fluticasone</a></td><td class="cBV"><b> ritonavir increases plasma concentration of <i>inhaled</i> and <i>intranasal</i> fluticasone </b></td><td></td></tr><tr><td><a href="41001i163.htm">Fusidic Acid</a></td><td class="cBV"><b>plasma concentration of both drugs increased when  ritonavir given with fusidic acid—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td> ritonavir increases plasma concentration of indinavir </td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td class="cBV"><b>combination of  ritonavir with itraconazole may increase plasma concentration of either drug (or both)</b></td><td></td></tr><tr><td><a href="41001i1050.htm">Ivabradine</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of ivabradine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td class="cBV"><b>combination of  ritonavir with ketoconazole may increase plasma concentration of either drug (or both)</b></td><td></td></tr><tr><td><a href="41001i283.htm">Lamotrigine</a></td><td> ritonavir possibly reduces plasma concentration of lamotrigine </td><td></td></tr><tr><td><a href="41001i1128.htm">Lapatinib</a></td><td class="cBV"><b>avoidance of  ritonavir advised by manufacturer of lapatinib </b></td><td></td></tr><tr><td><a href="41001i846.htm">Lercanidipine</a></td><td>avoidance of  ritonavir advised by manufacturer of lercanidipine </td><td></td></tr><tr><td><a href="41001i1107.htm">Maraviroc</a></td><td> ritonavir increases plasma concentration of maraviroc </td><td></td></tr><tr><td><a href="41001i97.htm">Methadone</a></td><td> ritonavir reduces plasma concentration of methadone </td><td></td></tr><tr><td><a href="41001i421.htm">Midazolam</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of midazolam (risk of prolonged sedation—avoid concomitant use of <i>oral</i> midazolam)</b></td><td></td></tr><tr><td><a href="41001i98.htm">Morphine</a></td><td> ritonavir possibly reduces plasma concentration of morphine </td><td></td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td>combination of  ritonavir with nelfinavir may increase plasma concentration of either drug (or both)</td><td></td></tr><tr><td><a href="41001i1118.htm">Nilotinib</a></td><td class="cBV"><b>avoidance of  ritonavir advised by manufacturer of nilotinib </b></td><td></td></tr><tr><td><a href="41001i60.htm">NSAIDs</a></td><td> ritonavir possibly increases plasma concentration of NSAIDs </td><td><i>See also </i>Aspirin. Interactions do not generally apply to topical NSAIDs
</td></tr><tr><td><a href="41001i636.htm">Oestrogens</a></td><td class="cBV"><b> ritonavir accelerates metabolism of oestrogens (reduced contraceptive effect—see <a title="target-block: COCs interactions" href="4552.htm#_120026">section 7.3.1</a>)</b></td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="4552.htm#_120026">section 7.3.1</a></td></tr><tr><td><a href="41001i366.htm">Olanzapine</a></td><td> ritonavir reduces plasma concentration of olanzapine—consider increasing dose of olanzapine</td><td></td></tr><tr><td><a href="41001i517.htm">Paclitaxel</a></td><td> ritonavir increases plasma concentration of paclitaxel </td><td></td></tr><tr><td><a href="41001i236.htm">Paroxetine</a></td><td> ritonavir possibly reduces plasma concentration of paroxetine </td><td></td></tr><tr><td><a href="41001i1186.htm">Pazopanib</a></td><td class="cBV"><b>avoidance of  ritonavir advised by manufacturer of pazopanib </b></td><td></td></tr><tr><td><a href="41001i102.htm">Pethidine</a></td><td class="cBV"><b> ritonavir reduces plasma concentration of pethidine , but increases plasma concentration of toxic metabolite of pethidine (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i223.htm">Phenindione</a></td><td class="cBV"><b> ritonavir possibly enhances anticoagulant effect of phenindione </b></td><td>Change in patient’s clinical condition particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control  </td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td>plasma concentration of  ritonavir possibly reduced by phenytoin , also plasma concentration of phenytoin possibly affected</td><td></td></tr><tr><td><a href="41001i369.htm">Pimozide</a></td><td class="cBV"><b> ritonavir increases plasma concentration of pimozide (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i78.htm">Piroxicam</a></td><td class="cBV"><b> ritonavir increases plasma concentration of piroxicam (risk of toxicity)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i486.htm">Prednisolone</a></td><td> ritonavir possibly increases plasma concentration of prednisolone </td><td></td></tr><tr><td><a href="41001i125.htm">Propafenone</a></td><td class="cBV"><b> ritonavir increases plasma concentration of propafenone (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i824.htm">Quetiapine</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of quetiapine—manufacturer of quetiapine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i341.htm">Quinine</a></td><td class="cBV"><b> ritonavir increases plasma concentration of quinine (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i1147.htm">Ranolazine</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i200.htm">Rifabutin</a></td><td class="cBV"><b> ritonavir increases plasma concentration of rifabutin (increased risk of toxicity—reduce rifabutin dose)</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>plasma concentration of  ritonavir possibly reduced by rifampicin </td><td></td></tr><tr><td><a href="41001i1136.htm">Rivaroxaban</a></td><td class="cBV"><b> ritonavir increases plasma concentration of rivaroxaban—manufacturer of rivaroxaban advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i974.htm">Rosuvastatin</a></td><td class="cBV"><b>possible increased risk of myopathy when  ritonavir given with rosuvastatin—manufacturer of rosuvastatin advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b> ritonavir increases plasma concentration of saquinavir </b></td><td></td></tr><tr><td><a href="41001i858.htm">Sildenafil</a></td><td class="cBV"><b> ritonavir significantly increases plasma concentration of sildenafil—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td class="cBV"><b>increased risk of myopathy when  ritonavir given with simvastatin (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i1020.htm">Solifenacin</a></td><td> ritonavir increases plasma concentration of solifenacin </td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>plasma concentration of  ritonavir reduced by St John's wort—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of tacrolimus </b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i945.htm">Tadalafil</a></td><td class="cBV"><b> ritonavir increases plasma concentration of tadalafil—manufacturer of tadalafil advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td> ritonavir possibly reduces plasma concentration of telaprevir </td><td></td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td class="cBV"><b>avoidance of concomitant  ritonavir in severe renal and hepatic impairment advised by manufacturer of telithromycin </b></td><td></td></tr><tr><td><a href="41001i734.htm">Theophylline</a></td><td class="cBV"><b> ritonavir accelerates metabolism of theophylline (reduced plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i1203.htm">Ticagrelor</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of ticagrelor—manufacturer of ticagrelor advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i275.htm">Tolbutamide</a></td><td> ritonavir possibly increases plasma concentration of tolbutamide </td><td></td></tr><tr><td><a href="41001i850.htm">Tolterodine</a></td><td>avoidance of  ritonavir advised by manufacturer of tolterodine </td><td></td></tr><tr><td><a href="41001i255.htm">Trazodone</a></td><td class="cBV"><b> ritonavir increases plasma concentration of trazodone (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i1163.htm">Ulipristal</a></td><td class="cBV"><b>avoidance of  ritonavir advised by manufacturer of ulipristal (contraceptive effect of ulipristal possibly reduced)</b></td><td></td></tr><tr><td><a href="41001i967.htm">Vardenafil</a></td><td class="cBV"><b> ritonavir increases plasma concentration of vardenafil—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1002.htm">Vinblastine</a></td><td> ritonavir possibly increases plasma concentration of vinblastine </td><td></td></tr><tr><td><a href="41001i1181.htm">Vinflunine</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of vinflunine—manufacturer of vinflunine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i948.htm">Voriconazole</a></td><td class="cBV"><b> ritonavir reduces plasma concentration of voriconazole—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i222.htm">Warfarin</a></td><td class="cBV"><b> ritonavir may enhance or reduce anticoagulant effect of warfarin </b></td><td></td></tr><tr><td><a href="41001i425.htm">Zolpidem</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of zolpidem (risk of extreme sedation and respiratory depression—avoid concomitant use)</b></td><td></td></tr></tbody></table><p><b>Saquinavir</b> belongs to
      <b>Antivirals</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>









































































<tr><td><a href="41001i86.htm">Alfentanil</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with alfentanil—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i118.htm">Amiodarone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with amiodarone—avoid concomitant use</b></td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i241.htm">Antidepressants, Tricyclic</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with tricyclics—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i293.htm">Antifungals, Imidazole</a></td><td>plasma concentration of  saquinavir possibly increased by imidazoles </td><td></td></tr><tr><td><a href="41001i300.htm">Antifungals, Triazole</a></td><td>plasma concentration of  saquinavir possibly increased by triazoles </td><td></td></tr><tr><td><a href="41001i1217.htm">Apixaban</a></td><td>avoidance of  saquinavir advised by manufacturer of apixaban </td><td></td></tr><tr><td><a href="41001i1011.htm">Aripiprazole</a></td><td class="cBV"><b> saquinavir possibly inhibits metabolism of aripiprazole (reduce dose of aripiprazole)</b></td><td></td></tr><tr><td><a href="41001i937.htm">Artemether with Lumefantrine</a></td><td>caution with  saquinavir advised by manufacturer of artemether/lumefantrine </td><td></td></tr><tr><td><a href="41001i1005.htm">Atazanavir</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with atazanavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i601.htm">Atorvastatin</a></td><td>possible increased risk of myopathy when  saquinavir given with atorvastatin </td><td></td></tr><tr><td><a href="41001i1204.htm">Cabazitaxel</a></td><td class="cBV"><b>avoidance of  saquinavir advised by manufacturer of cabazitaxel </b></td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td>plasma concentration of  saquinavir possibly reduced by carbamazepine </td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b>plasma concentration of both drugs increased when  saquinavir given with ciclosporin </b></td><td></td></tr><tr><td><a href="41001i744.htm">Cimetidine</a></td><td>plasma concentration of  saquinavir possibly increased by cimetidine </td><td></td></tr><tr><td><a href="41001i168.htm">Clarithromycin</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with clarithromycin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i364.htm">Clozapine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with clozapine—avoid concomitant use</b></td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr><tr><td><a href="41001i161.htm">Dapsone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with dapsone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1076.htm">Darifenacin</a></td><td>avoidance of  saquinavir advised by manufacturer of darifenacin </td><td></td></tr><tr><td><a href="41001i1091.htm">Darunavir</a></td><td> saquinavir reduces plasma concentration of darunavir </td><td></td></tr><tr><td><a href="41001i490.htm">Dexamethasone</a></td><td>plasma concentration of  saquinavir possibly reduced by dexamethasone </td><td></td></tr><tr><td><a href="41001i119.htm">Disopyramide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with disopyramide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1176.htm">Dronedarone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with dronedarone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td>plasma concentration of  saquinavir significantly reduced by efavirenz </td><td></td></tr><tr><td><a href="41001i1025.htm">Eplerenone</a></td><td> saquinavir increases plasma concentration of eplerenone (reduce dose of eplerenone)</td><td></td></tr><tr><td><a href="41001i563.htm">Ergotamine and Methysergide</a></td><td class="cBV"><b>increased risk of ergotism when  saquinavir given with ergotamine and methysergide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i169.htm">Erythromycin</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with erythromycin—avoid concomitant use</b></td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i914.htm">Esomeprazole</a></td><td class="cBV"><b>plasma concentration of  saquinavir possibly increased by esomeprazole—manufacturer of saquinavir advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1169.htm">Everolimus</a></td><td class="cBV"><b> saquinavir possibly increases plasma concentration of everolimus—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i95.htm">Fentanyl</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with fentanyl—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1119.htm">Fesoterodine</a></td><td>manufacturer of fesoterodine advises dose reduction when  saquinavir given with fesoterodine—consult fesoterodine product literature</td><td></td></tr><tr><td><a href="41001i120.htm">Flecainide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with flecainide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i387.htm">Haloperidol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with haloperidol—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td>plasma concentration of  saquinavir increased by indinavir </td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td>plasma concentration of  saquinavir increased by ketoconazole </td><td></td></tr><tr><td><a href="41001i753.htm">Lansoprazole</a></td><td class="cBV"><b>plasma concentration of  saquinavir possibly increased by lansoprazole—manufacturer of saquinavir advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1128.htm">Lapatinib</a></td><td class="cBV"><b>avoidance of  saquinavir advised by manufacturer of lapatinib </b></td><td></td></tr><tr><td><a href="41001i55.htm">Lidocaine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with lidocaine—avoid concomitant use</b></td><td>Interactions less likely when lidocaine used topically</td></tr><tr><td><a href="41001i922.htm">Lopinavir</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with lopinavir—avoid concomitant use</b></td><td>In combination with ritonavir as <i>Kaletra</i>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</td></tr><tr><td><a href="41001i1107.htm">Maraviroc</a></td><td class="cBV"><b> saquinavir increases plasma concentration of maraviroc (consider reducing dose of maraviroc)</b></td><td></td></tr><tr><td><a href="41001i97.htm">Methadone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with methadone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i421.htm">Midazolam</a></td><td class="cBV"><b> saquinavir increases plasma concentration of midazolam (risk of prolonged sedation—avoid concomitant use of <i>oral</i> midazolam)</b></td><td></td></tr><tr><td><a href="41001i841.htm">Mizolastine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with mizolastine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td class="cBV"><b>plasma concentration of  saquinavir increased by nelfinavir—manufacturer of saquinavir advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i752.htm">Omeprazole</a></td><td class="cBV"><b>plasma concentration of  saquinavir increased by omeprazole—manufacturer of saquinavir advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i754.htm">Pantoprazole</a></td><td class="cBV"><b>plasma concentration of  saquinavir possibly increased by pantoprazole—manufacturer of saquinavir advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1186.htm">Pazopanib</a></td><td class="cBV"><b>avoidance of  saquinavir advised by manufacturer of pazopanib </b></td><td></td></tr><tr><td><a href="41001i808.htm">Pentamidine Isetionate</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with pentamidine isetionate—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td class="cBV"><b>plasma concentration of  saquinavir possibly reduced by phenobarbital </b></td><td></td></tr><tr><td><a href="41001i373.htm">Phenothiazines</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with phenothiazines—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td>plasma concentration of  saquinavir possibly reduced by phenytoin </td><td></td></tr><tr><td><a href="41001i369.htm">Pimozide</a></td><td class="cBV"><b> saquinavir possibly increases plasma concentration of pimozide (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i125.htm">Propafenone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with propafenone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i824.htm">Quetiapine</a></td><td class="cBV"><b> saquinavir possibly increases plasma concentration of quetiapine—manufacturer of quetiapine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i341.htm">Quinine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with quinine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i869.htm">Rabeprazole</a></td><td class="cBV"><b>plasma concentration of  saquinavir possibly increased by rabeprazole—manufacturer of saquinavir advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1147.htm">Ranolazine</a></td><td class="cBV"><b> saquinavir possibly increases plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i200.htm">Rifabutin</a></td><td class="cBV"><b> saquinavir increases plasma concentration of rifabutin (also plasma concentration of saquinavir reduced)</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>plasma concentration of  saquinavir significantly reduced by rifampicin , also risk of hepatotoxicity—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  saquinavir increased by ritonavir </b></td><td></td></tr><tr><td><a href="41001i1136.htm">Rivaroxaban</a></td><td>avoidance of  saquinavir advised by manufacturer of rivaroxaban </td><td></td></tr><tr><td><a href="41001i974.htm">Rosuvastatin</a></td><td class="cBV"><b>possible increased risk of myopathy when  saquinavir given with rosuvastatin—manufacturer of rosuvastatin advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i858.htm">Sildenafil</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with sildenafil—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td class="cBV"><b>increased risk of myopathy when  saquinavir given with simvastatin (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i455.htm">Sotalol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with sotalol—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>plasma concentration of  saquinavir reduced by St John's wort—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td class="cBV"><b> saquinavir increases plasma concentration of tacrolimus (consider reducing dose of tacrolimus)</b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i945.htm">Tadalafil</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with tadalafil—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td class="cBV"><b>avoidance of concomitant  saquinavir in severe renal and hepatic impairment advised by manufacturer of telithromycin </b></td><td></td></tr><tr><td><a href="41001i1055.htm">Tipranavir</a></td><td class="cBV"><b>plasma concentration of  saquinavir reduced by tipranavir </b></td><td></td></tr><tr><td><a href="41001i850.htm">Tolterodine</a></td><td>avoidance of  saquinavir advised by manufacturer of tolterodine </td><td></td></tr><tr><td><a href="41001i255.htm">Trazodone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with trazodone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i967.htm">Vardenafil</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with vardenafil—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i222.htm">Warfarin</a></td><td> saquinavir possibly enhances anticoagulant effect of warfarin </td><td></td></tr></tbody></table><p><b>Stavudine</b> belongs to
      <b>Antivirals</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>





<tr><td><a href="41001i397.htm">Didanosine</a></td><td class="cBV"><b>increased risk of side-effects when  stavudine given with didanosine </b></td><td>Antacids in tablet formulation may affect absorption of other drugs</td></tr><tr><td><a href="41001i506.htm">Doxorubicin</a></td><td>effects of  stavudine possibly inhibited by doxorubicin </td><td></td></tr><tr><td><a href="41001i1052.htm">Hydroxycarbamide</a></td><td class="cBV"><b>increased risk of toxicity when  stavudine given with hydroxycarbamide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i953.htm">Ribavirin</a></td><td class="cBV"><b>increased risk of toxicity when  stavudine given with ribavirin </b></td><td></td></tr><tr><td><a href="41001i403.htm">Zidovudine</a></td><td class="cBV"><b>effects of  stavudine possibly inhibited by zidovudine (manufacturers advise avoid concomitant use)</b></td><td>Increased risk of toxicity with nephrotoxic and myelosuppressive drugs—for further details consult product literature</td></tr></tbody></table><p><b>Zidovudine</b> belongs to
      <b>Antivirals</b>
          and has the following interaction information:
        </p><div>Increased risk of toxicity with nephrotoxic and myelosuppressive drugs—for further details consult product literature</div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>














<tr><td><a href="41001i431.htm">Atovaquone</a></td><td>metabolism of  zidovudine possibly inhibited by atovaquone (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i168.htm">Clarithromycin</a></td><td>absorption of  zidovudine reduced by clarithromycin tablets (give at least 2 hours apart)</td><td></td></tr><tr><td><a href="41001i301.htm">Fluconazole</a></td><td class="cBV"><b>plasma concentration of  zidovudine increased by fluconazole (increased risk of toxicity)</b></td><td>In general, fluconazole interactions relate to multiple-dose treatment</td></tr><tr><td><a href="41001i395.htm">Ganciclovir</a></td><td class="cBV"><b>profound myelosuppression when  zidovudine given with ganciclovir (if possible avoid concomitant administration, particularly during initial ganciclovir therapy)</b></td><td>Increased risk of myelosuppression with other myelosuppressive drugs—consult product literature</td></tr><tr><td><a href="41001i97.htm">Methadone</a></td><td>plasma concentration of  zidovudine possibly increased by methadone </td><td></td></tr><tr><td><a href="41001i60.htm">NSAIDs</a></td><td>increased risk of haematological toxicity when  zidovudine given with NSAIDs </td><td><i>See also </i>Aspirin. Interactions do not generally apply to topical NSAIDs
</td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td> zidovudine increases or decreases plasma concentration of phenytoin </td><td></td></tr><tr><td><a href="41001i663.htm">Probenecid</a></td><td class="cBV"><b>excretion of  zidovudine reduced by probenecid (increased plasma concentration and risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i340.htm">Pyrimethamine</a></td><td>increased antifolate effect when  zidovudine given with pyrimethamine </td><td></td></tr><tr><td><a href="41001i953.htm">Ribavirin</a></td><td class="cBV"><b>increased risk of anaemia when  zidovudine given with ribavirin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>manufacturer of  zidovudine advises avoid concomitant use with rifampicin </td><td></td></tr><tr><td><a href="41001i401.htm">Stavudine</a></td><td class="cBV"><b> zidovudine possibly inhibits effects of stavudine (manufacturers advise avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i1055.htm">Tipranavir</a></td><td class="cBV"><b>plasma concentration of  zidovudine reduced by tipranavir </b></td><td></td></tr><tr><td><a href="41001i286.htm">Valproate</a></td><td>plasma concentration of  zidovudine possibly increased by valproate (increased risk of toxicity)</td><td></td></tr></tbody></table></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="41001i1216.htm" title="Telaprevir">Telaprevir</a></li><li><a href="41001i1214.htm" title="Boceprevir">Boceprevir</a></li><li><a href="41001i1135.htm" title="Etravirine">Etravirine</a></li><li><a href="41001i1019.htm" title="Fosamprenavir">Fosamprenavir</a></li><li><a href="41001i1112.htm" title="Telbivudine">Telbivudine</a></li><li><a href="41001i1111.htm" title="Raltegravir">Raltegravir</a></li><li><a href="41001i1107.htm" title="Maraviroc">Maraviroc</a></li><li><a href="41001i1091.htm" title="Darunavir">Darunavir</a></li><li><a href="41001i1088.htm" title="Adefovir">Adefovir</a></li><li><a href="41001i1055.htm" title="Tipranavir">Tipranavir</a></li><li><a href="41001i1005.htm" title="Atazanavir">Atazanavir</a></li><li><a href="41001i998.htm" title="Emtricitabine">Emtricitabine</a></li><li><a href="41001i954.htm" title="Tenofovir">Tenofovir</a></li><li><a href="41001i953.htm" title="Ribavirin">Ribavirin</a></li><li><a href="41001i952.htm" title="Foscarnet">Foscarnet</a></li><li><a href="41001i951.htm" title="Cidofovir">Cidofovir</a></li><li><a href="41001i907.htm" title="Abacavir">Abacavir</a></li><li id="_41001i392"><a href="41001i392.htm" title="Aciclovir">Aciclovir</a></li><li><a href="41001i397.htm" title="Didanosine">Didanosine</a></li><li><a href="41001i874.htm" title="Efavirenz">Efavirenz</a></li><li><a href="41001i393.htm" title="Famciclovir">Famciclovir</a></li><li id="_41001i395"><a href="41001i395.htm" title="Ganciclovir">Ganciclovir</a></li><li><a href="41001i398.htm" title="Indinavir">Indinavir</a></li><li><a href="41001i399.htm" title="Lamivudine">Lamivudine</a></li><li><a href="41001i922.htm" title="Lopinavir">Lopinavir</a></li><li><a href="41001i842.htm" title="Nelfinavir">Nelfinavir</a></li><li><a href="41001i843.htm" title="Nevirapine">Nevirapine</a></li><li><a href="41001i400.htm" title="Ritonavir">Ritonavir</a></li><li><a href="41001i791.htm" title="Saquinavir">Saquinavir</a></li><li><a href="41001i401.htm" title="Stavudine">Stavudine</a></li><li><a href="41001i403.htm" title="Zidovudine">Zidovudine</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i390.htm">Previous: Zuclopenthixol</a> | <a class="top" href="41001i391.htm#">Top</a> | <a accesskey="]" href="41001i1216.htm">Next: Telaprevir</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>